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General introduction
Dementia, a syndrome of brain dysfunction, has many possible causes. Alzheimer's 
disease (AD) is the most common cause of dementia.(1) It is a progressive neuro- 
degenerative disorder that is characterized neuropathologically by the deposition of 
amyloid (3 protein (A(3) -containing extracellular amyloid plaques, intracellular neuro­
fibrillary tangles (NFTs), and neuronal loss. AD patients gradually develop memory 
loss and other cognitive deficits, such as aphasia, apraxia, agnosia, and impaired 
executive functioning. Also, neuropsychiatric disturbances such as personality 
changes, depression, psychosis, anxiety, and agitation are common in AD patients.
(2) It has a devastating effect on the life of patients, and places a great burden on 
their caregivers.
AD affects millions of individuals worldwide, and its prevalence increases with 
age.(3). The ageing of populations in most western world countries implies that the 
number of patients will increase even further in the near future, with great socio­
economic consequences for western societies. So far there are no drugs available 
that prevent, cure or slow the progression of the disease. The currently available 
treatments such as cholinesterase inhibitors (e.g. rivastigmine, galantamine, done- 
pezil), and memantine, an N-methyl-D-aspartate receptor antagonist, only offer a 
moderate symptomatic effect.(4)
Since 1982, a growing number of investigators has studied the role of inflam­
mation in the pathogenesis of AD, and the consequent hypothesis that AD can be 
treated with anti-inflammatory drugs.(5-7) Through extensive neuropathological, 
epidemiological, and animal research evidence has been compiled that an inflamma­
tory process actively mediates AD pathology, and that the use of anti-inflammatory 
drugs, in particular non-steroidal anti-inflammatory drugs (NSAIDs), may lower the 
risk of developing AD.(8-10) However, there is still insufficient evidence that NSAIDs 
can actually cure or slow the progression of AD; Clinical trials have failed to prove 
that NSAIDs have a neuroprotective effect in this disease.
When conducting a clinical trial testing an NSAID in AD patients, there are two 
important issues to consider. First, it is crucial to choose the most appropriate NSAID 
to study, since the mechanism of action differs between the various NSAIDs, espe­
cially regarding AD pathology.(11-13) Also, the selected NSAID should be able to
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cross the blood-brain barrier. Second, it is important to include the proper patients in 
clinical trials. AD patients should be distinguished carefully from patients with other 
dementia types such as vascular dementia, frontotemporal lobar degeneration, and 
dementia with Lewy bodies, since all dementia types have a different pathogen­
esis and a different clinical course. An accurate AD diagnosis is not only necessary 
for research purposes, but also essential for appropriate support and (symptomatic) 
treatment of AD patients. However, with the current clinical diagnostic criteria it is 
still impossible to adequately discriminate between the different dementias.(14;15) 
Other biomarkers, such as the quantification of brain-specific proteins in cerebro­
spinal fluid (CSF), may help to improve this selection.
Ap protein is the major component of amyloid plaques, and tau protein the 
primary constituent of NFTs in brains of AD patients. Therefore, these proteins 
were first regarded as potential diagnostic biomarkers in CSF of dementia patients. 
Decreased concentrations of A042, and increased concentrations of total tau pro­
tein, which includes both normal and hyperphosphorylated tau, were found in CSF 
of AD patients compared to controls.(16;17) Different levels of these proteins were 
found in other dementia types compared to AD, which improves the discrimination 
between different dementia types.(18-20) However, additional CSF biomarkers and 
novel technologies are necessary to further improve this discrimination.
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Aims and outline of this thesis
The content of this thesis is divided in two coherent parts. The first part of this thesis 
concerns the treatment of Alzheimer disease (AD), especially with nonsteroidal anti­
inflammatory drugs (NSAIDs). The second part relates on the diagnosis of AD using 
biomarkers in cerebrospinal fluid (CSF).
Alzheimer's disease and anti-inflammatory drugs
The aim of this part of the thesis was to review the role of inflammation in the patho­
genesis of AD, and to study the effect of one NSAID, indomethacin, on the progression 
of AD. In addition, the external validity of randomized controlled trials (RCTs) with 
AD patients was explored.
In chapter 2.1 we review different lines of research that address AD and 
inflammation. We reviewed which NSAID is the best candidate to study in a clini­
cal trial with AD patients; indomethacin appeared to be one of the most promising 
NSAIDs. The methods and results of a double-blind, randomized, placebo-controlled 
trial with indomethacin in AD patients are described in chapter 2.2. Furthermore, 
we investigated the characteristics of all patients that participated in our trial, and 
compared them with all remaining AD patients seen at our memory clinic for diag­
nosis and treatment during the four-year recruitment period of the trial. This study 
of the external validity of the results of our trial is presented in chapter 2.3. Also, 72 
RCTs with AD patients testing various drugs were selected from the literature and 
reviewed for further comparisons.
Cerebrospinal fluid diagnosis in Alzheimer's disease
The aim of this part of the thesis was to investigate whether the analysis of biomarkers, 
especially in CSF, may be helpful in discriminating AD from other dementias.
In chapter 3.1 we describe the results of the analysis of CSF levels of total tau 
protein, amyloid 042 protein, and tau phosphorylated at threonine 181 in AD patients 
compared to patients with vascular dementia. The diagnostic value of another CSF 
biomarker, neurofilament (NF) protein, is described in chapter 3.2. We investigated 
the diagnostic value of NF analysis to discriminate in relatively young dementia 
patients between frontotemporal lobar degeneration and early-onset AD, and in
13
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elderly dementia patients between dementia with Lewy bodies and late-onset AD.
Chapter 3.3 is a review of the literature regarding neurochemical biomarkers for
AD. We summarize the current state-of-the-art of biomarkers for AD in CSF and in
plasma.
In chapter 4.1, the main findings of the thesis are summarized followed by a discus­
sion and recommendations for future research.
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Abstract
Ever since inflammatory mediators were detected surrounding amyloid plaques in 
brains of patients with Alzheimer's disease (AD), researchers have been interested 
in the role of inflammatory mechanisms in AD and its potential treatment with anti­
inflammatory drugs. Epidemiological studies have already demonstrated that use of 
nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk for 
the development of AD. The effect of NSAIDs in AD is probably mediated by activa­
tion of the peroxisome proliferator-activated receptor-y. Administration of NSAIDs 
to AD mice suppressed plaque formation and inflammation. Together, these findings 
raised the suggestion that NSAIDs will be able to retard AD progression. So far, only 
one small clinical trial has shown that treatment with NSAIDs significantly delayed 
cognitive decline in AD patients. Large randomized double-blind placebo-controlled 
trials are needed to demonstrate a definite beneficial effect of NSAIDs in AD.
The possible suppression o f A lzheim er's disease by nonsteroidal an tl- ln flam m atory drugs
Introduction
Since 1982, when complement factors were found present in amyloid plaques in 
brains of patients with Alzheimer's disease (AD), the role of inflammation in the 
pathogenesis of this disease gained interest.(l) In 1990, the results of epidemiologi­
cal studies in patients with rheumatoid arthritis suggested that the prolonged use 
of anti-inflammatory drugs might have a protective effect on incipient AD (primary 
prevention).(2) This generated the hypothesis that anti-inflammatory drugs could 
also have a therapeutic effect on patients already suffering from AD (secondary 
prevention). In 1993, the positive results of a small double blind placebo-controlled 
trial that tested the effect of indomethacin, a nonsteroidal anti-inflammatory drug 
(NSAID), in AD patients supported this hypothesis.(3)
Ever since, many studies have been published that investigated inflammation and 
anti-inflammatory therapy in AD. However, a significant effect of an anti-inflamma- 
tory drug in a randomized controlled trial had not yet been found. As all the currently 
registered drugs for AD, co-dergocrine, rivastigmine, galantamine, and memantine, 
have only a limited symptomatic effect, the hypothesis that the use of inexpensive 
anti-inflammatory drugs can prevent or retard the progression of AD remains attrac­
tive.
In the following paragraphs the inflammatory hypothesis, and the clinical 
applicability of the most promising anti-inflammatory drugs in AD, the NSAIDs, will 
be discussed.
Neuropathological data
The most characteristic neuropathological changes in the brains of AD patients are 
amyloid plaques, that consist of extraneuronal accumulations of amyloid-p (A(3) 
protein, and neurofibriHairy tangles, formed by intraneuronal deposits of tau pro­
tein. The numbers of plaques and tangles have been found to correlate significantly 
with disease severity.(4) They probably cause neuronal dysfunction and cell death, 
that eventually leads to clinical symptoms of the disease. As plaques and tangles 
are foreign and disruptive elements in brain tissue, they may initiate an immuno-
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logical reaction. However, granulocytes and lymphocytes, elements of the classical 
acute immunological response, are conspicuously absent. Instead, amyloid plaques 
are surrounded by macrophage-like cells called microglia. In vitro research demon­
strated that microglia are activated by A(3 protein present in amyloid plaques. Acti­
vated microglia appear to play a role in the transformation of diffuse amyloid plaques, 
also present in some non-demented elderly persons, into neuritic amyloid plaques.
(5) In addition, activated microglia produce proteins that play a role in inflammation, 
like complement factors, proinflammatory cytokines and chemokines (interleukin 
(IL)-1, IL-6, transforming growth factor (TGF)-p and tumor necrosis factor (TNF)-a). 
They also generate primary neurotoxic products such as free radicals and nitric oxide 
(NO).(6) Not only the products produced by microglia, but also other inflammatory 
mediators can be found in and around plaques and tangles (table 1).(7) The resulting 
inflammatory response causes tissue damage; and this again may be pro-inflamma- 
tory in itself.
Table 1
Inflammatory mediators in Alzheimer's disease
Acute phase proteins C-reactive protein, al-antichymotrypsin, a2-macroglobulin, 
amyloid P component
Adhesion molecules Intercellular adhesion molecules (ICAM-1 and ICAM-2)
Complement factors Cl q, C2, C3, C4, C5, C6, C7, C9, C5b-9
Complement inhibitors Cl inhibitor, C4-binding protein
Cytokines and chemokines lnterleukin-1 a, interleukin 6, tumor necrosis factor-a, 
transforming growth factor-(3
Epidemiological data
If inflammation plays a role in the development or progression of AD, prolonged use 
of anti-inflammatory drugs should lower the risk of AD. This hypothesis has been 
tested in many epidemiological studies. Despite differences in design and methods 
of these studies, they all show a remarkable consistent picture of an association 
between the use of NSAIDs and a lower risk of AD (table 2).
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Table 2
Risk of Alzheimer's disease while using non-steroidal anti-inflammatory drugs (NSAIDs); 
results of epidemiological research
Study Publication
year
Design OR/RR (95% Cl) Duration 
NSAID use
McGeer (8) 1996 Case-control 0,50 (0,34 - 0,72) variable
Stewart (9) 1997 Prospective 0,40 (0,19-0,84) > 2 years
Beard (10) 1998 Case-control 0,79(0,45- 1,38) variable
In'tVeld (11) 1998 Case-control 0,68 (0,21 -2,14) > V2 yea r
Anthony (12) 2000 Case-control 0,47 (0,24 - 0,90) variable
In'tVeld (13) 2001 Prospective 0,20 (0,05 - 0,83) > 2 year
OR/RR = odds ratio or relative risk; Cl = confidence interval
In 1996, a meta-analysis of 17 epidemiological studies was published investigating 
the use of anti-inflammatory drugs by patients with arthritis, and their riskfor AD: 14 
were case-control studies.(8) Pooling seven of these studies with anti-inflammatory 
drug use as risk factor, an odds ratio (OR) of 0,556 (p < 0,0001) was found. For four 
studies with steroids the OR was 0,656 (p = 0,049), and for three studies with NSAIDs 
the OR was 0,496 (p = 0,0002).(8)
Results of epidemiological studies published after 1996 supported these ini­
tial findings.(9-13) Furthermore, an additionally decreased risk of AD was found with 
prolonged versus short term use of NSAIDs, especially among those with two or 
more years of NSAID use.(9;11; 13) In the most recent prospective study the relative 
risk of AD was 0,95 (95 %  Cl, 0,70 - 1,29) in subjects with short-term use of NSAIDs 
(one month or less of cumulative use).(13) In those with intermediate-term use (more 
than 1 but less than 24 months), risk was 0,83 (95 %  Cl, 0,62 - 1,11), and 0.20 (95 %  
Cl, 0.05 to 0.83) in those with long-term use (24 months or more). No significant risk 
reduction was found in long-term users of salicylates.(13)
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Mechanism of action of NSAIDs
Inhibition of cyclooxygenase (COX), responsible for the conversion of arachidonic 
acid into inflammatory mediators such as prostaglandins, was considered the most 
important mechanism of action of NSAIDs. The two COX iso-enzymes, COX-1 and 
COX-2, are both inhibited by classical NSAIDs. Inhibition of COX-2 seems mainly 
responsible for the anti-inflammatory effect. However, the effects of NSAIDs can not 
be solely of mainly ascribed to inhibition of COX, since anti-inflammatory effects will 
only be reached at much higher doses than necessary for the inhibition of COX. This 
suggests another mechanism of action.(14)
An alternative mechanism of action of NSAIDs may be the activation of the 
peroxisome proliferator-activated receptor-gamma (PPAR-y). Since 1997 the role 
of PPAR-y in inflammation, and the effect of NSAIDs on this receptor, has received 
much interest. PPAR-y is a nuclear receptor that, when activated, yields an anti­
inflammatory effect. Most classical NSAIDs, such as indomethacin, naproxen, and 
ibuprofen are agonists of PPAR-y, with the exception of diclofenac, which is only 
a partial agonist.(15;16) It has been demonstrated that PPAR-y agonists inhibit the 
Ap-stimulated activation of microglia, and thus prevent the excretion of pro-inflam- 
matory and directly neurotoxic products.(17) Also, PPAR-y agonists appear to reduce 
the NO mediated apoptotic cell death by inhibiting inducible NO-synthetase.(18) 
Contrary to COX-inhibition, activation of PPAR-y can explain previous findings such 
as the in vitro suppression of the production of pro-inflammatory cytokines (IL-1 
and IL-6), and the reduction of NO-production and apoptosis by NSAIDs.(19;20) It 
also explains the previously demonstrated suppression of microglia activation in 
postmortem brain tissue of elderly non-demented individuals who were chronically 
exposed to anti- inflammatory drugs.(21)
Another potential mechanism of action of NSAIDs is the reduction of A042 
formation and the inhibition of the formation of neuritic amyloid plaques. A042 is 
the 42 amino-acid long easily aggregating form of A(3 protein that, in contrast to 
the isoforms Af^s and AP40, is mainly held responsible for the initiation of neuritic 
amyloid plaques. In vitro research has demonstrated that the NSAIDs ibuprofen and 
indomethacin not only lower the amount of A042, but also increase the amount of 
the less aggregating isoform AP38. This may be caused by an effect on the action
24
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of y-secretase, one of the enzymes responsible for the formation of A(3 from the 
amyloid precursor protein (APP). However, not all NSAIDs exert this effect. Naproxen, 
meloxicam (a non-selective COX-2 inhibitor), SC-560 (a selective COX-1 inhibitor), 
and salicylic acid were not able to suppress A042 secretion.(22)
Animal models
Animal models appear to offer the most pertinent model systems to test the effects 
of anti-inflammatory drugs. The frequently used transgenic mouse model Tg2576 
overexpresses a mutant form of APP, causing an elevated production of A(34o and 
A042. These animals develop age-related neuritic amyloid plaques, and impairment 
in learning and memory. Administration of ibuprofen during six months toTg2576 
mice reduced the amount of A(3 deposits, the number of activated microglia, and 
IL-1 (3 production.(23) Specifically, it was the amount of A042 that was decreased.(22) 
Also, studies in non-transgenic animal models supported the efficacy of NSAIDs. 
Chronic infusion of soluble A(3 during two weeks in the lateral ventricles of rats caused 
extraneuronal depositions of A(3, and the activation of microglia that surround the 
ventricles. This A(3 induced microglial activation was significantly attenuated in ani­
mals receiving concurrent intravenous treatment with indomethacin.(24)
Clinical data
The ultimate proof of the clinical relevance of the inflammatory hypothesis and the 
efficacy of NSAIDs on the development and progression of AD can only be provided 
by placebo-controlled clinical trials. Until 2002, only five clinical trials had been 
published.
In the first double-blind, placebo-controlled trial published in 1993, 44 AD 
patients were treated with either placebo or 100-150 mg/day indomethacin during 
a 6 month period.(3) When the results of the Alzheimer's Disease Assessment Scale 
(ADAS), Mini-Mental State Examination, Boston Naming Test and Token Test were 
combined in an aggregate score, patients treated with indomethacin had improved
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1,3%, and patients receiving placebo had declined 8,4%. However, the results of the 
individual cognitive tests appeared not significantly different between groups. Com­
bined with a large percentage of drop-outs (16 patients), the interpretation of the 
results of this small study is difficult.
In a second pilot trial in 41 AD patients, diclofenac was combined with miso­
prostol.(25) After six months a nonsignificant trend was found for patients in the pla­
cebo group to have deteriorated more than diclofenac/misoprostol-treated patients, 
as measured on the cognitive subscale of the ADAS (ADAS-cog). The small group of 
patients, together with a relatively large withdrawal rate (14 patients), may explain 
the non-significant results of this study.(25)
In 2000 the results of a third trial with prednisone in 138 AD patients were pub­
lished.(26) After one year of treatment, no difference in cognitive decline (ADAS-cog) 
between groups could be found. However, the results of this study are potentially 
obscured by the occurrence of behavioral problems in the prednisone group.(26)
The results of a fourth trial with the selective COX-2 inhibitor celecoxib in 425 
AD patients were presented in 2000 (S.M. Sainali, written communication, 2000). 
After one year of treatment, cognitive decline (ADAS-cog) in the celecoxib and the 
placebo group was not significantly different.
In the fifth trial, the antimalarial drug with anti-inflammatory qualities hydroxy­
chloroquine was compared to placebo.(27) Again, after 18 months cognitive decline 
(ADAS-cog), as well as decline in activities of daily living, was similar in both groups.
(27)
Appropriate NSAIDs for further trials in AD
If one intends to study whether NSAIDs can retard the cognitive decline in AD, the 
selection of the NSAID to be investigated becomes crucial. Pharmacological and 
pharmacokinetic properties then take center stage (table 3). As COX-inhibition by 
NSAIDs appears not to play an important role, the choice of a selective COX-2 inhibitor 
is not obvious, despite the favorable side-effects profile. Decreasing the production 
ofA042 through an effect on y-secretase also seems irrelevant; this would only have a
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primary preventive effect, i.e. when the neuritic plaques still have to be formed. The 
preferred NSAIDs have agonistic effects on PPAR-y, since it is expected that they will 
be able to retard the progression of AD.
Table 3
Properties of various non-steroidal anti-inflammatory drugs
Drug COX-inhibition PPAR-y
agonist
Effect on 
Aß production
Blood-brain 
barrier passage
Salicylic acid COX-1 ? no yes
Celecoxib COX-2 ? no ?
Diclofenac COX-1 + 2 partial ? yes
Ibuprofen COX-1 + 2 yes yes yes
Indomethacin COX-1 + 2 yes yes yes
Naproxen COX-1 + 2 yes no yes
COX = cyclooxygenase; PPAR-y = peroxisome proliferator-activated receptor-gamma; 
A(3 = amyloid-(3 protein; ? = unknown.
The classical NSAIDs ibuprofen, indomethacin, and naproxen are PPAR-y agonists, 
they pass the blood-brain barrier, and moreover they are cheap.(28) Based on the 
present information, one of these NSAIDs would be preferred as investigational drug 
in AD patients. However, an important disadvantage will be the expected side-effects, 
especially the gastro-intestinal side-effects. These may be countered by adding a 
proton pump inhibitor or misoprostol, but this increases the treatment costs.
Therefore, we started a randomized double-blind placebo-controlled clini­
cal trial with indomethacin and the proton pump inhibitor omeprazole in 160 AD 
patients at the Radboud University Nijmegen Medical Center, and at the Rijnstate 
Hospital, Arnhem, The Netherlands. In the United States of America, a similar study is 
being conducted with naproxen and the COX-2 selective NSAID rofecoxib. Hopefully, 
the results of these studies will provide answers to the question whether NSAIDs 
have a therapeutic effect in AD, and which NSAID is the most appropriate.
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Abstract
Objectives: To determine whether treatment with the nonselective nonsteroidal 
anti-inflammatory drug (NSAID) indomethacin slows cognitive decline in patients 
with Alzheimer's disease (AD).
Design: A double-blind, randomized, placebo-controlled trial.
Setting: The study was conducted between May 2000 to September 2005 in two 
hospitals in the Netherlands.
Participants: 51 patients with mild to moderate AD were enrolled into the study. 
Interventions: Patients received 100 mg indomethacin or placebo daily for 12 
months. Additionally, all patients received omeprazole.
Outcome measures: The primary outcome measure was the change from baseline 
after one year of treatment on the cognitive subscale of the AD Assessment Scale 
(ADAS-cog). Secondary outcome measures included the Mini-Mental State Examina­
tion, the Clinician's Interview Based Impression of Change with caregiver input, the 
noncognitive subscale of the ADAS, the Neuropsychiatric Inventory, and the Inter­
view for Deterioration in Daily life in Dementia.
Results: Considerable recruitment problems of participants were encountered, lead­
ing to an underpowered study. In the placebo group, 19 out of 25 patients completed 
the study, and 19 out of 26 patients in the indomethacin group. The deterioration 
on the ADAS-cog was less in the indomethacin group (7.8 ± 7.6), than in the placebo 
group (9.3 ± 10.0). This difference (1.5 points; Cl -4.5 - 7.5) was not statistically signifi­
cant, and neither were any of the secondary outcome measures.
Conclusion: The results of this study are inconclusive with respect to the hypothesis 
that indomethacin slows the progression of AD.
Trial Registration: NCT00432081.
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Introduction
Early indications that inflammation plays an important role in the pathogenesis of 
Alzheimer's disease (AD) emerged in 1982, when complement factors were found in 
senile plaques.(1) Many studies followed that supported the inflammatory hypothesis, 
and evidence accumulated that anti-inflammatory drugs, in particular nonsteroidal 
anti-inflammatory drugs (NSAIDs) would either prevent, postpone or treat AD.(2) How­
ever, 25 years later, there is still no clinical evidence that NSAIDs have an effect in AD 
patients, nor is there incontrovertible evidence of the contrary.
In a small randomized controlled trial, the traditional NSAID indomethacin 
appeared to protect AD patients from cognitive decline.(3) Another small random­
ized controlled trial studying the effect of diclofenac/misoprostol in AD, found a non­
significant trend of more advanced deterioration in the placebo group than in the 
diclofenac/misoprostol group.(4) A large randomized controlled trial with naproxen 
(440 mg/d) could not confirm the earlier observed trends.(5) Both pilot studies were 
hampered by high withdrawal rates in the treatment groups due to side effects. Low- 
dose naproxen was reasonably well tolerated.
The side effects of NSAIDs, e.g. gastrointestinal toxicity, have always been a 
major concern that limited their use. It was suggested that the beneficial actions 
of NSAIDs are linked to their ability to inhibit cyclooxygenase-2 (COX-2), while their 
side effects result from inhibition of COX-1.(6) However, randomized controlled trials 
with COX-2 selective NSAIDs (rofecoxib, nimesulide, and celecoxib) failed to show an 
effect on the progression of AD.(5;7-9) Consequently, the traditional nonselective 
NSAIDs regained interest.
Apart from the promising, but never replicated, results of the initial indometha­
cin trial, there are also in vitro and animal model studies that support a possible thera­
peutic effect. Indomethacin inhibited amyloid (3 (AP)-induced neurotoxicity,(10-12) 
and decreased the production of Ap-protein, interleukin-6, interleukin-1, nitric oxide, 
and prostaglandin E2 in a variety of cultured cells.(13-18) Furthermore, indometha­
cin was found to have anti-amyloidogenic effects in vitro; The formation of A|3 fibrils 
was dose-dependently inhibited by indomethacin.(19) In rats, indomethacin attenu­
ated microglial infiltration, and improved lipopolysaccharide-induced amnesia. 
(20;21) In a transgenic mouse-model of AD-like amyloidosis (Tg2576), indomethacin
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suppressed brain levels of prostaglandins,(22) and reduced A(3 levels in cortex and 
hippocampus.(22;23) This amyloid burden lowering effect was confirmed by other 
investigators using a combination of indomethacin and vitamin E to treat Tg2576 
mice.(24)
Supported by these data, particularly by the prior trial that suggested a thera­
peutic benefit as well as by its potential A(3 lowering effect, we hypothesized that 
indomethacin may retard the clinical progression of AD.
Methods
Participants
Patients were recruited from May 2000 to August 2004 at the Department of Neurol­
ogy and at the Memory Clinic, Department of Geriatric Medicine of the Radboud 
University Nijmegen Medical Center, and at the Memory clinic of the Department of 
Geriatric Medicine, Rijnstate Hospital, Arnhem, The Netherlands. Patients were eli­
gible if they met the NINCDS/ADRDA criteria for the clinical diagnosis of probable 
AD,(25) had mild or moderate dementia as measured by a Mini-Mental State Exami­
nation (MMSE)(26) score between 10 and 26 inclusive, and were living at home or 
in a home for the elderly. Patients had to be supported by a reliable caregiver, who 
accompanied them to each clinic visit in order to provide information about the 
patient's functional status, and who would ensure that the participants took their 
test medication.
Patients were excluded if they had a history or current evidence of peptic 
ulceration; history of gastric surgery or gastrointestinal bleeding; severe and unsta­
ble cardiovascular disease; severe pulmonary disease; renal failure (serum creati­
nine greater than 200 mmol/l); clinically significant liver disease (plasma aspartate 
and alanine aminotransferase levels three times the upper limit of normal); poorly 
controlled diabetes mellitus; hypersensitivity to NSAIDs or aspirin; alcohol abuse; 
or advanced, severe and unstable disease of any type (other than AD), that might 
interfere with evaluations during the study, including a medical condition which 
should be expected to progress, recur, or change to such an extent that it might 
bias the assessment of the clinical or mental status of the patient, or put the patient
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at special risk. Also, patients taking the following concomitant medications were 
excluded, because of a possible interaction with indomethacin; aspirin, coumarin 
derivatives, angiotensin converting enzyme inhibitors, loop diuretics, and long-term 
use of other NSAIDs or corticosteroids (more than two months immediately before 
study entry). Intake of the following medication was not allowed during the study 
because of a possible effect on cognition; estrogen replacement therapy, deprenyl, 
vitamin E, neuroleptics and anticholinergic medication. Patients using stable doses 
of cholinesterase inhibitors were eligible, with the provision that the dose should 
not be changed during the study. Cholinesterase inhibitors could not be initiated 
during the study.
At both study sites, approval of the local institutional review board to perform 
the study was received. Informed consent was obtained from each patient and their 
legally acceptable representative.
Interventions
The study was a one-year, randomized, double-blinded, placebo-controlled bicenter 
trial. After screening, patients were randomly assigned to receive 50 mg indometha­
cin twice daily or placebo twice daily for one year. In addition, patients in both treat­
ment groups received omeprazole 20 mg once daily, to prevent gastrointestinal side 
effects.
Objectives
We tested whether indomethacin would have an effect on cognitive and behavioral 
dysfunction, as well as dysfunction of the activities of daily living, in patients with 
mild to moderate AD.
Outcomes
Efficacy was primarily assessed by the cognitive subscale of the AD Assessment Scale 
(ADAS-cog),(27) an instrument that evaluates memory, language, attention, reason­
ing, orientation, and praxis (range 0 to 70). Secondary outcome measures included 
the MMSE,(26) the Clinician's Interview Based Impression of Change with caregiver 
input (CIBIC+),(28) the noncognitive subscale of the ADAS (ADAS-noncog),(27) the 
Neuropsychiatric Inventory (NPI),(29;30) including the NPI caregiver distress scale
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(NPI-D),(31) and the Interview for Deterioration in Daily life in Dementia (IDDD).(32) 
The IDDD is a caregiver-based measure, which consists of 20 concretely worded 
items that reflect the initiative to perform, and the actual performance of self-care 
and more complex activities.
Cognitive and behavioral assessments were performed at baseline, and at 
weeks 26 and 52. Safety assessments included vital signs and the recording and 
rating of any adverse event by the investigator (weeks 4, 8, 12, 26, 38, and 52), 
physical examination (baseline, week 26, and 52), and routine hematology and 
chemistry blood tests (baseline, week 4,8, 26, and 52).
Sample size
The primary hypothesis tested was that indomethacin would be superior to placebo 
in retarding cognitive decline as measured on the ADAS-cog after one year of treat­
ment. We aimed at 80% power to detect a 3-point difference in the change in ADAS- 
cog score after one year between patients who received indomethacin and those 
who received placebo. ADAS-cog data from previous studies were used in the power 
calculations for the initial trial, and an SD of 7 was assumed. This yielded a estimated 
sample size of 67 to be evaluated per group. Since an overall dropout rate of 20% 
was anticipated, the required sample size was 80 patients per group.
Randomization - Sequence Generation
The statistician provided computer-generated lists of random numbers allocating 
patients in a 1:1 ratio to receive indomethacin or placebo. For each center, a separate 
randomization list was provided.
Randomization - Allocation Concealment
Randomization codes were held by the pharmacy of the Radboud University 
Nijmegen Medical Center that labeled and dispensed all trial medication. Allocation 
was concealed from all investigators and patients.
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Randomization - Implementation
Eligible patients were allocated to a randomization number in the same order they 
were enrolled in the trial at both trial sites. At each visit, patients received a supply 
of medication (indomethacin or placebo) by the pharmacy, labeled with their ran­
domization number.
Blinding
The indomethacin and placebo tablets were of identical appearance. Neither the 
patients nor the investigators knew which treatment they received or dispensed. 
The blinding process remained complete until all data was entered in the trial data­
base and the accuracy of the data and the database was confirmed. Afterward, the 
database was forwarded to the statistician for analysis.
Statistical methods
The changes from baseline in the groups were compared using analysis of covari­
ance with the baseline results of each assessment as a covariate. In an additional 
analysis, gender and age were added as covariates. Two-sided p values and 95% 
confidence intervals were calculated. The primary efficacy analysis was conducted 
on the observed values. In addition, the last observation carried forward (LOCF) 
approach was used.
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Participant flow and recruitment
Figure 1 illustrates the flow of patients through the study protocol. The study was 
discontinued prematurely after four years, due to difficulties with the enrollment
Figure 1 
Trial profile
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of patients into the study. Based on an inclusion rate of approximately thirteen 
patients per year, eight more years of enrollment would have been necessary to 
complete this study. Taking into account scientific, organizational, and financial rea­
sons, the decision was made to discontinue the study. Eventually, fifty-one patients 
were included in the trial, about one-thirds of the number originally anticipated. 
Most patients were enrolled at the Memory Clinic, Department of Geriatric Medi­
cine of the Radboud University Nijmegen Medical Center (n = 46), with an inclusion 
rate of one out of every five to six patients diagnosed with AD. The remainder of 
patients was enrolled at the outpatient clinic of the Department of Neurology of the 
Radboud University Nijmegen Medical Center (n = 3), and at the Department of Geri­
atric Medicine of the Rijnstate Hospital, Arnhem (n = 2).
Numbers analyzed
Twenty-five patients were randomly assigned to the placebo group, and twenty-six 
patients to the indomethacin group. Completion rates were 19 of 25 patients (76%) 
in the placebo group, and 19 of 26 patients (73%) in the indomethacin group. One 
patient in the indomethacin group discontinued the study in week 48 due to care­
giver issues, but completed all week 52 evaluations. The predominant reasons for 
premature study discontinuation were adverse events (n = 6) in the indomethacin 
group, and withdrawal of consent (n = 2) in the placebo group. None of the patients 
that withdrew from the study due to adverse events did complete their follow-up 
assessments, however all other available assessment data were included in the 
analysis.
Baseline data
Treatment groups were similar with respect to demographic and baseline clinical 
characteristics, except for gender distribution (table 1); in the placebo group 24% of 
patients were male, and in the indomethacin group 46% of patients. No significant 
differences were found between baseline assessment scores. Nevertheless, baseline 
NPI, NPI-D, and ADAS-noncog scores were higher in the indomethacin group, sug­
gesting that patients in this group had more behavioral problems.
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Table 1
Baseline characteristics of the study population by treatment group
Characteristics Placebo Indomethacin
(n = 25) (n = 26)
Men / women 6/19 12/14
Age (SD), years 72.2 (9.0) 72.7 (6.9)
Education level (SD), range 1 to 5* 2.7 (0.9) 2.4 (1.3)
>1 APOE £4 allele, n (%) 11 (44%) 13 (50%)
Disease duration (SD), months 31.1 (19.6) 32.9(17.4)
Use of Cholinesterase inhibitor, n (%) 2 (8,0%) 2 (7.7%)
MMSE score (SD) 20.2 (3.9) 19.1 (4.1)
ADAS-cog score (SD) 19.7 (8.8) 20.2 (8.3)
ADAS-noncog score (SD) 2.8 (2.7) 3.5 (3.6)
NPI score (SD) 7.1 (6.7) 11.2(12.0)
NPI-D score (SD) 5.6 (4.5) 7.7 (7.3)
IDDD score (SD) 21.2(12.8) 22.8(13.7)
* level 1 is primary school only; level 5 is university level.
Outcomes, estimation, and ancillary analyses
The effect of treatment on primary and secondary outcome measures is shown in 
table 2. The decrease in mean ADAS-cog score after one year of therapy was 1.5 
points less in the indomethacin group (7.8 ± 7.6) compared to the placebo group 
(9.3 ± 10.0), however this was not statistically significant (Cl -4.5 - 7.5). When using 
the LOCF approach to analyze the difference in change in ADAS-cog score, or when 
gender and age were included as covariate in the analysis, the results were similar to 
the primary analysis (data not shown).
The decline of secondary outcome measures after six months or one year of treat­
ment did not show statistically significant differences between groups either (table 
2). Additional analysis, using the LOCF approach, showed similar results.
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Table 2
Mean change from baseline of outcome measures, and difference in scores between 
the placebo and indomethacin group, after six and twelve months of treatment
Placebo group 
mean change from 
baseline (SD)
Indomethacin group 
mean change from 
baseline (SD)
Difference between 
groups*
(95% Cl)
Measure 6 months 
(n = 23)
1 year 
(n = 19)
6 months 
(n = 20)
1 year 
(n = 19)
6 months 1 year
ADAS-cog 3.9 (4.5) 9.3 (10.0) 4.8 (5.8) 7.8 (7.6) -0.9
(-4.1 - 2.2)
1.5
(-4.5 - 7.5)
ADAS-
noncog
-0.3 (1.5) 1.6 (4.2) 1.5 (4.1) 3.8 (6.7) -1.8
(-3.9 - 0.2)
-2.8
(-6.7- 1.1)
MMSE -2.4 (3.6) -5.4 (5.5) -2.3 (3.2) -3.4 (4.3) 0.1
(-1.9- 2.1)
1.6
(-1.6-4.8)
NPI -0.3 (4.9) 9.4(14.0) 1.7 (14.0) 3.2(18.1) -3.6
(-10.1 -2.9)
4.6
(-6.6 - 15.8)
NPI-D -0.9 (3.5) 6.5 (8.8) 0.7 (6.4) 1.4 (8.3) -2.2
(-5.4- 1.0)
4.6
(-1.3-10.5)
IDDD 10.4 (8.3) 18.2(14.8) 9.5 (14.4) 19.4(13.8) 0.8
(-6.4 - 8.0)
-1.5
(-11.0-8.0)
CIBIC+ 5.3 (0.7) 5.7 (0.7) 5.1 (0.8) 5.6 (0.8) 0.2
(-0.2 - 0.6)
0.1
(-0.3 - 0.5)
* differences, adjusted for baseline (analysis of covariance)
Negative change in scores from baseline indicates improvement, with the exception of the 
MMSE score (positive change indicates improvement), and the CIBIC+ (higher score means 
worse compared to baseline). Positive difference between groups means in favor of the 
indomethacin group, for all measures.
Adverse Events
Blood test abnormalities, abnormalities found during physical examination, and 
adverse events reported on case report forms were grouped into categories for analy­
sis. Adverse events that occurred in at least two patients in either treatment group 
are listed in table 3. Patients in the indomethacin group had more frequent adverse
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events. Dyspepsia, epigastic pain, or abdominal distress or pain, were reported more 
frequently in the placebo group (n = 3), than in the indomethacin group (n = 1). 
In both groups, there were no reports of serious gastrointestinal adverse events, 
such as gastroenteritis, ulceration or bleeding. Nausea, dizziness, and hyperglyce­
mia were more common in the indomethacin group, whereas diarrhea, constipation, 
and headache, were more common in the placebo group. Weight loss, defined as 5 
percent or more loss of body weight, was seen in three patients in the indomethacin 
group, and in one patient in the placebo group. New cases of hypertension were 
reported more frequently in the indomethacin group (5 out of 22 non-hypertensive 
patients at baseline; 23%), than in the placebo group (2 out of 18 non-hyperten- 
sive patients at baseline; 11%). Despite these cases of elevated blood pressure, the 
change in mean arterial pressure (MAP) during the trial was not significantly different 
between groups; MAP increased 2.5 ± 10.6 (mean ± SD) mmHg in the indomethacin 
group, and decreased 1.2 ± 9.5 mmHg in the placebo group (p = 0.20).
Table 3
Adverse events that occurred in at least two patients in either treatment group
Placebo Indomethacin
Adverse event and omeprazole and omeprazole
(n = 25) (n = 26)
Nausea 0 2
Diarrhea or constipation 3 2
Dyspepsia, epigastric or abdominal pain 3 1
Weight loss (> 5% during the study) 1 3
Headache 2 0
Dizziness 1 3
Hyperglycemia 1 2
Hypertension (new cases) 2 5
Serious adverse events were also more common in the indomethacin group (n = 5) 
than in the placebo group (n = 1; table 4), and reason for study withdrawal (table 4). In 
the indomethacin group, blood tests revealed a considerable elevation of creatinine
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levels (> 1.5 times the upper limit of normal) in three patients, without clinical symp­
toms. All three patients had abnormal creatinine clearance rates before entering the 
trial, and one of these patients had a history of nephrectomy. After discontinuation 
of the study, serum creatinine levels returned to their previous levels. Blood tests 
also revealed increased levels (> 3 times the upper limit of normal) of alanine ami­
notransferase, and aspartate aminotransferase in one patient in the indomethacin 
group, without clinical symptoms. Liver function tests normalized within four weeks 
after study discontinuation. Nine days after enrollment in the study, one patient in 
the indomethacin group had a lacunar stroke. Evaluation after four months of recov­
ery revealed only minor disabilities (increased memory impairment and irritability). 
Death occurred in one patient in the placebo group after 38 weeks of study partici­
pation.The cause of death of this patient is unknown.
Table 4
Serious adverse events
Serious adverse event
Placebo
and omeprazole 
(n = 25)
Indomethacin 
and omeprazole 
(n = 26)
Elevated creatinine* 0 3
Abnormal liver function tests1" 0 1
Stroke (lacunar) 0 1
Death 1 0
* > 1.5 times the upper limit of normal; + > 3 times the upper limit of normal
Discussion
Interpretation
In this study, indomethacin 50 mg twice daily did not show any statistically signifi­
cant effects on the progression of dementia in patients with mild to moderate AD 
during a 1-year period, as measured by testing of cognition, behavior, and activities 
of daily living, and by overall clinical global impression.
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Although our study included more patients than the earlier trials with indomethacin 
and diclofenac/misoprostol, the number of included patients was still too small.(3;4) 
Thus, the study was clearly underpowered, resulting in very wide confidence inter­
vals; The confidence interval for the ADAS-cog was 12 points (range -4.5 to 7.5).This 
means that the difference between the groups should have been at least 6 points to 
reach statistical significance.
Generalizability
The enrollment of patients was hampered by the extensive exclusion criteria, 
especially the exclusion of patients using aspirin, angiotensin converting enzyme 
inhibitors or loop diuretics. The institutional review board specifically imposed this 
criterion, since interaction of these drugs with indomethacin might aggravate the 
occurrence of side effects of indomethacin. Not only did patient enrollment suffer 
from these strict criteria, it is also responsible for another limitation of the study; Our 
study population was a highly selected group of AD patients, with no or minor car­
diovascular comorbidity, and thus not representative of the average AD population.
Overall evidence
By its nature our study cannot prove that anti-inflammatory drugs in general and indo­
methacin in particular are ineffective. However, the study outcome is consistent with 
earlier trials that investigated prednisone, hydroxychloroquine, and various selective 
and non-selective NSAIDs in similar designs; All these studies failed to demonstrate a 
beneficial effect on disease progression.(4;5;7-9;33;34) These failures may have been 
due to the pharmacokinetic or pharmacological properties of the drugs being used. 
But it may also be questioned whether anti-inflammatory treatment will ever be effi­
cacious in treating symptomatic AD. Although they may have preventive effects, they 
may no longer be effective in patients with established disease.
Indomethacin in combination with omeprazole was reasonably well tolerated 
in this elderly population. There were no serious gastrointestinal tract events. Dys­
pepsia, epigastic pain, or abdominal distress or pain were more common in the pla­
cebo group, and may have been caused by omeprazole, and not by indomethacin. 
However, elderly patients should be carefully monitored when using indomethacin. 
Blood pressure should be checked regularly, and blood tests must be done before
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and during indomethacin treatment. In patients with elevated creatinine clearance, 
the administration of indomethacin should be avoided.
In conclusion, the results of this study are inconclusive with respect to the 
hypothesis that indomethacin slows the progression of AD. Owing to its limited sta­
tistical power, this study does not alter the conclusions from earlier trials that NSAIDs 
do not appear to be effective in altering the progression of symptoms in AD. Thus, 
treatment of AD patients with indomethacin should currently not be recommended, 
and further treatment trials with NSAIDs in AD patients should be thoroughly recon­
sidered. However, primary prevention trials with NSAIDs, in particular ibuprofen (in 
combination with omeprazole), are warranted to further investigate the effect of 
long-term NSAID use on risk of AD.
References
(1) Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. 
An immunoperoxidase study. Acta Neuropathol Berl 1982;57(2-3):239-242.
(2) McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: Epidemiological, animal model 
and clinical studies. Neurobiol Aging 2006 May 10;28(5):639-647.
(3) Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's 
disease. Neurology 1993;43(8):1609-1611.
(4) Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled 
trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999 Jul 13;53(1):197-201.
(5) Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo 
on Alzheimer disease progression: a randomized controlled trial. JAMA 2003 Jun 
4;289(21):2819-2826.
(6) Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 
1998;38:97-120.
(7) Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer's disease in a 
1-year, randomized, blinded, controlled study. Neurology 2004 Jan 13;62(1 ):66-71.
(8) Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in 
Alzheimer's disease. Neurology 2002 Apr 9;58(7):1050-1054.
(9) Sainati SM, Ingram DM.Talwalker S, Geis GS. Results of a double-blind placebo-controlled 
study of celecoxibforthe progression of Alzheimer's disease. Proceedings ofthe sixth Inter­
national Stockholm-Springfield Symposium of advances in Alzheimer therapy 2000;p.180.
45
Chapter 2.2
(10) Dzenko KA, Weltzien RB, Pachter JS. Suppression of A beta-induced monocyte neurotox­
icity by antiinflammatory compounds. J Neuroimmunol 1997;80(1-2):6-12.
(11) Fagarasan MO, Efthimiopoulos S. Mechanism of amyloid beta-peptide (1-42) toxicity in 
P C I2 cells. Mol Psychiatry 1996 Nov;1 (5):398-403.
(12) Fagarasan MO, Aisen PS. IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity 
in PC12 cells. Brain Res 1996;723(1-2):231-234.
(13) Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 inde­
pendently of cyclooxygenase activity. Nature 2001 Nov 8;414(6860):212-216.
(14) Kadoyama K, Takahashi Y, Higashida H.TanabeT, YoshimotoT. Cyclooxygenase-2 stimu­
lates production of amyloid beta-peptide in neuroblastoma x glioma hybrid NG108-15 
cells. Biochem Biophys Res Commun 2001 Feb 23;281 (2):483-490.
(15) Blom MA, van Twillert MG, de Vries SC, et al. NSAIDS inhibit the IL-1 beta-induced IL-6 
release from human post-mortem astrocytes: the involvement of prostaglandin E2. Brain 
Res 1997;777(1 -2):210-218.
(16) Bour AM, Westendorp RG, Laterveer JC, Bollen EL, Remarque EJ. Interaction of indo- 
methacin with cytokine production in whole blood. Potential mechanism for a brain- 
protective effect. Exp Gerontol 2000 Oct;35(8):1017-1024.
(17) Hoozemans JJ, Veerhuis R, Janssen I, Rozemuller AJ, Eikelenboom P. Interleukin-1 beta 
induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuro­
blastoma cells: implications for Alzheimer's disease. Exp Gerontol 2001 Mar;36(3):559-570.
(18) Du ZY, Li XY. Inhibitory effects of indomethacin on interleukin-1 and nitric oxide produc­
tion in rat microglia in vitro. Int J Immunopharmacol 1999 Mar;21 (3):219-225.
(19) Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-inflammatory drugs have anti- 
amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology 
2005 Dec;49(7):1088-1099.
(20) Netland EE, Newton JL, Majocha RE, Tate BA. Indomethacin reverses the microglial 
response to amyloid beta-protein. Neurobiol Aging 1998 May;19(3):201 -204.
(21) Ma TC, Zhu XZ. Suppression of lipopolysaccharide-induced impairment of active avoid­
ance and interleukin-6-induced increase of prostaglandin E2 release in rats by indometa- 
cin. Arzneimittelforschung 1997;47(5):595-597.
(22) Sung S,Yang H, Uryu K, et al. Modulation of nuclear factor-kappa B activity by indometha­
cin influences A beta levels but not A beta precursor protein metabolism in a model of 
Alzheimer's disease. Am J Pathol 2004 Dec;165(6):2197-2206.
(23) Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D, Eckenstein F. Inflammation 
and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. 
J  Neuroimmunol 2003 Apr;137(1-2):32-41.
46
No effect of one-year treatm ent w ith  indom ethacin  on Alzheim er's disease progression
(24) Yao Y, Chinnici C,Tang H.Trojanowski JQ, Lee VM, Pratico D. Brain inflammation and oxi­
dative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroin­
flammation 2004 Oct 22;1 (1):21.
(25) McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis 
of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of 
Department of Health and Human Services Task Force on Alzheimer's Disease. Neurol­
ogy 1984 Jul;34(7):939-944.
(26) Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading 
the cognitive state of patients for the clinician. J  Psychiatr Res 1975 Nov;12(3):189-198.
(27) Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 
1984 Nov;141 (11):1356-1364.
(28) Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression 
(CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994 
Dec;44(12):2315-2321.
(29) Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neu­
ropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. 
Neurology 1994 Dec;44(12):2308-2314.
(30) Kat MG, de Jonghe JF, Aalten P, Kalisvaart CJ, Droes RM, Verhey FR. Neuropsychiatric 
symptoms of dementia: psychometric aspects of the Dutch Neuropsychiatric Inventory 
(NPI). Tijdschr Gerontol Geriatr 2002 Sep;33(4):150-155.
(31) Kaufer Dl, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric 
symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress 
Scale. J Am Geriatr Soc 1998 Feb;46(2):210-215.
(32) Teunisse S, Derix MM. The interview for deterioration in daily living activities in dementia: 
agreement between primary and secondary caregivers. Int Psychogeriatr 1997;9 Suppl 
1:155-162.
(33) Aisen PS, Davis KL, Berg JD .eta l. A randomized controlled trial of prednisone in Alzheimer's 
disease. Alzheimer's Disease Cooperative Study. Neurology 2000 Feb 8;54(3):588-593.
(34) van Gool WA, Weinstein HC, Scheltens PK, Walstra GJ. Effect of hydroxychloroquine on 
progression of dementia in early Alzheimer's disease: an 18-month randomised, double­
blind, placebo-controlled study. Lancet 2001 Aug 11;358(9280):455-460.
47

Chapter 2.3
External validity of 
a randomized controlled trial 
in Alzheimer's disease
D. de Jong
H.P.H. Kremer 
M.M. Verbeek 
G.F. Borm 
R.W.M.M. Jansen
Submitted
Chapter 2.3
Abstract
Objectives: To investigate the external validity of the results of a randomized 
controlled trial (RCT) with indomethacin in Alzheimer's disease (AD) patients, and 
evaluate the generalizability of other drug-trials in AD patients.
Design: Retrospective study / review.
Setting: Memory clinic.
Participants: All AD patients that participated in a RCT with indomethacin (RCT 
group, n = 51), versus all remaining AD patients seen at the memory clinic for diag­
nosis and treatment during the four-year recruitment period of the trial (control 
group, n = 128).
Measurements: Characteristics of patients, such as medication use, comorbidity, 
results of physical and neurological examination, were collected. The Cumulative Ill­
ness Rating Scale for geriatrics (CIRS-G) was used to assess the presence and severity 
of comorbidity. Furthermore, 72 RCTs with AD patients testing various drugs were 
selected from the literature for further comparisons.
Results: Age of the RCT group was significantly lower (72.4 ± 8.0 years) compared to 
the control group (76.1 ± 6.5 years; p<0.01). Furthermore, the RCT group had fewer 
disabilities and comorbid conditions, and were taking less medication, than the con­
trol group. In 62 out of 72 evaluated other RCTs, mean age of participating patients 
was < 76 years. In only 11 RCT articles, some information was available on medica­
tion use or comorbidity of participants.
Conclusion: The external validity of the results of our RCT with indomethacin and 
of many other RCTs with AD patients is limited. Care should be taken to extrapolate 
conclusions from clinical trials to a general population of AD patients.
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Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that afflicts 
millions of people worldwide, and this number is expected to increase significantly 
in the coming decades. Since 1990, many randomized controlled trials (RCTs) have 
been conducted in AD patients testing different types of drugs. RCTs are considered 
the gold standard for determining the efficacy and safety of treatment. To be clini­
cally useful, the results of RCTs should be relevant to patients in routine clinical prac­
tice, i.e. the external validity, generalizability or applicability should be high.(1;2) 
The external validity of RCTs, however, may be limited by stringent protocol-driven 
conditions, such as restrictions in disease severity, co-morbid conditions, and con­
comitant medications, as well as limited follow-up periods and sample sizes. These 
conditions, and many others, have to be taken into account when interpreting the 
results of an RCT. More specifically, physicians should consider if patients in their 
care might respond differently to treatment than patients studied in a clinical trial.
Despite the fact that numerous drug-treatment trials have been conducted 
in AD, there are only a few reports reviewing the quality of these RCTs. The external 
validity of an RCT with the cholinesterase inhibitor tacrine has been discussed, in 
which an enrichment strategy was used.(1;3;4) In this study, 632 AD patients were 
first enrolled in a run-in phase, in which their responsiveness to tacrine and best dose 
was determined. After a washout period, only patients who had an improvement on 
tacrine (n = 215) were randomly assigned to receive either placebo or their best dose 
of tacrine in the double-blind main phase of the trial. This approach undermines the 
generalizability of the results of this trial. Nevertheless, other RCTs were conducted 
using the same controversial strategy.(5-7)
Another study discussed the high selection of AD patients recruited to drug 
trials.(8) The authors investigated the records of 279 AD patients seen in their clinic 
who were all candidates for drug trials. From these patients, only 36 patients were 
enrolled in a clinical trial (13%). There were various reasons for non-enrollment, for 
example theoccurrenceof behavioral symptoms that required treatment (n = 61), and 
concomitant diseases (n = 30). Enrollment was more likely to occur in patients with 
higher Mini-Mental State Examination (MMSE) scores,(9) higher schooling level, and 
younger age. Other investigators found that AD patients, who provisionally fulfilled
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the selection criteria of two different clinical trials, were better educated, wealthier, 
more likely to be white, younger, and relatively underrepresented by women.(10) 
Furthermore, they found that more than 60% of patients were excluded because of 
significant behavioral problems, and approximately one-quarter because of signifi­
cant medical or neurological problems. The age-gap between dementia patients in 
clinical studies and dementia patients in the general population, was also addressed. 
(11) These investigators concluded that dementia research is systematically biased 
towards patients who are relatively young compared to the general dementia popu­
lation.
Discussing external validity of AD drug trials raises many questions. Are AD 
patients who are mainly recruited in research centers comparable to patients from 
a community-based outpatient clinic or memory clinic? Do common eligibility and 
exclusion criteria lead to a selection bias in groups of AD patients? Is the general 
health of patients included in RCTs similar to that of patients in routine daily prac­
tice? Since most published trial reports list only a few baseline characteristics (usually 
age, race, disease duration, and MMSE score), these questions cannot be answered. 
It should be noted that the importance of measuring the presence and severity of 
comorbidity in effectiveness studies in AD was already addressed in 1997.(12)
Based on the observations described above, we hypothesize that AD patients 
participating in RCTs evaluating the effect of different drugs are not representative 
of AD patients seen in routine daily practice. In order to address this, we studied the 
characteristics of the patients who visited our memory clinic, and compared them to 
the characteristics of patients we had enrolled in a RCT conducted by ourselves,(13) 
as well as to patients who were enrolled in published trials. Our formal aim was to 
analyze how our inclusion and exclusion criteria potentially affected the validity of a 
trial like the one we published.
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Methods
Patients
AD patients that entered the control group were selected from patients referred by 
family physicians or other medical specialists to the memory clinic of the Radboud 
University Nijmegen Medical Center, between April 2000 and April 2004 (a total of 
420 patients). In the Netherlands, AD patients eligible for treatment are diagnosed 
and treated at memory clinics, or alternatively at an outpatient clinic of a Geriatric 
Medicine or Neurology Department, especially since prescription of cholinesterase 
inhibitors is restricted to geriatricians and neurologists. There is only one memory 
clinic in the region of Nijmegen, thus the AD population seen at our clinic may be a 
good representation of AD patients from the general population eligible for drug- 
treatment. All patients followed an extensive diagnostic examination protocol. The 
final diagnosis was based on the NINCDS/ADRDA criteria,(14) and was established 
by a panel of geriatricians and a neurologist specialized in dementia. All patients 
diagnosed with probable AD that were not participating in the RCT with indometha- 
cin, were included in the control group (n = 128).
The RCT group consisted of AD patients that participated in our previously 
described RCT with the nonsteroidal anti-inflammatory drug (NSAID) indomethacin 
(n = 51).(13) During a four-year period (2000 to 2004), patients were recruited at the 
memory clinic of the Department of Geriatric Medicine (n = 46), and at the outpa­
tient clinic of the Department of Neurology (n = 3) of the Radboud University Nijme­
gen Medical Center, as well as at the memory clinic of the Department of Geriatric 
Medicine, Rijnstate Hospital, Arnhem, the Netherlands (n = 2). Patients were eligible 
if they met the NINCDS/ADRDA criteria for the clinical diagnosis of probable AD,(14) 
had mild or moderate dementia as measured by a MMSE score between 10 and 26 
inclusive, were living at home or in a home for the elderly, and were supported by a 
reliable caregiver. Patients were excluded if they had a history or current evidence of 
peptic ulceration; history of gastric surgery or gastrointestinal bleeding; severe and 
unstable cardiovascular disease; severe pulmonary disease; renal failure (serum crea­
tinine > 200 mmol/l); clinically significant liver disease (plasma aspartate and alanine 
aminotransferase levels three times the upper limit of normal); poorly controlled 
diabetes mellitus; hypersensitivity to NSAIDs or aspirin; alcohol abuse; or advanced,
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severe and unstable disease of any type (other than AD), that might interfere with 
evaluations during the study, or put the patient at special risk. Also, patients taking 
the following concomitant medications were excluded, because of a possible inter­
action with indomethacin; aspirin, coumarin derivatives, angiotensin converting 
enzyme (ACE) inhibitors, loop diuretics, corticosteroids, and other NSAIDs. Intake of 
the following medication was not allowed during the study because of a possible 
effect on cognition; estrogen replacement therapy, deprenyl, vitamin E, neuroleptics, 
and anticholinergic medication. It should be emphasized that subjects not included 
in the RCT were included in the control group.
Data collection
Data on duration of the disease, severity of cognitive impairment, medical history, 
medication, intoxications, level of education, functional impairment, gait disorders, 
physical and neurological examination, neuropsychological testing, laboratory 
testing, and imaging of the brain were extracted from the medical charts.
Outcome measures
For the current analysis the MMSE score was included,(9) since this rapid neuropsy­
chological test was assessed in almost every patient (control group, n = 120 (94%); 
RCT group, n = 51 (100%)). Severity of dementia was rated using the Clinical Demen­
tia Rating scale.(15) Duration of the disease was defined as time in years between 
first symptoms and diagnosis. Level of education was rated on a scale of 1 (primary 
school level) to 5 (university level). The level of dependence of patients on their 
caregivers regarding the activities of daily living (ADL) and instrumental activities 
of daily living (IADL) was scored as follows: (0) independent, (1) partially dependent,
(2) dependent. Height and weight were used to calculate the Body Mass Index (BMI). 
Mean arterial pressure (MAP) of patients was calculated using values of systolic and 
diastolic blood pressure. Plasma concentrations of sodium, potassium, creatinine, 
glucose, haemoglobin, and TSH were recorded, and out of range plasma concentra­
tions were registered. Laboratory results of a patient were scored abnormal if one or 
more test results were out of range.
The Cumulative Illness Rating Scale for geriatrics (CIRS-G) was used to assess 
comorbidity.(16;17) This rating scale scores the presence and severity of comorbid
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disease in 14 organ-specific categories (heart; vascular; haematopoietic; respiratory; 
eyes, ears, nose and throat and larynx; upper gastrointestinal tract; lower gastro­
intestinal tract; liver; renal; genitourinary tract; musculoskeletal/integument; neuro­
logical; endocrine/metabolic and breast; and psychiatric illness).The worst problem 
in each category is rated on a scale from 0 to 4 (0 = no comorbidity; 4 = extremely 
severe/immediate treatment required/end-organ failure/severe impairment in func­
tion). We excluded category 14 (psychiatric illness), since this item scores the pres­
ence and severity of dementia. Two scores were calculated: (1) the total CIRS-G score, 
which is the sum score of all 13 organ-specific categories, and (2) the CIRS-G severity 
index, which is the ratio of the total score and the number of endorsed categories.
Polypharmacy was defined as use of five or more drugs.(18) Only prescription 
drugs that were taken on a regular basis (not as-needed) were included. All drugs 
were categorized in different drug classes to enable subgroup analysis.
Statistical analysis
The two-sample t- test and the chi-squared test were used for group comparisons. In 
addition, analysis of covariance and logistic regression were carried out, with covariate 
age. Pearson's correlation coefficient was used for analyzing correlations. Results with 
two-sided p-value less than 0.05 were considered statistically significant.
Comparison with published trials
MEDLINE and PubMed (1990 to March 2009) were systematically searched using the 
terms Alzheimer's disease, and randomized clinical trial. All articles were reviewed 
using the following predetermined inclusion criteria: (1) the trial was randomized, 
double-blinded, and placebo-controlled; (2) patients enrolled were diagnosed as 
having mild to moderate AD; (3) thirty or more participating patients; (4) the trial 
involved 12 or more weeks of continuous drug treatment; (5) the effect on cognitive 
function was measured with the cognitive subscale of the Alzheimer Disease Assess­
ment Scale (ADAS-cog); and (6) data were available about age, and selection criteria 
of patients. After identification of all relevant trials, we extracted the following infor­
mation; diagnostic criteria used for AD, inclusion criteria (MMSE score range, age 
range), exclusion criteria, trial duration, number of participating sites, mean age of 
participating patients, and availability of baseline characteristics of patient groups
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(gender, race, level of education, MMSE score, duration of the disease, weight, con­
comitant diseases, and concomitant medication). In addition, we calculated mean 
age, and mean MMSE score of participating patients.
Table 1
Clinical characteristics of Alzheimer's disease patients in the control group and 
the randomized controlled trial group
Control group 
(n = 128)
RCT group 
(n = 51) p-value
Age, years 76.1 ±6.5 72.4 ± 8.0 < 0.01
Sex (male/female), % 34/66 35/65 0.91
MMSE score 18.2 ± 5.5 19.7 ±4.0 0.24
Clinical Dementia Rating scale 1.4 ± 0.6 1.3 ± 0.6 0.35
Disease duration, years 2.5 ± 2.0 2.7 ± 1.5 0.15
Level of education* 2.3 ±1.3 2.5 ± 1.1 0.22
Smoking, n (% ) 23 (21) 10 (20) 0.85
Alcohol, units/week 4.1 ±6.9 4.5 ± 7.1 0.75
ADL dependence score+ 0.4 ± 0.7 0.1 ± 0.3 < 0.01
IADL dependence score+ 1.2 ±0.7 1.0 ±0.5 < 0.05
Gait disorder, n (% ) 18(14) 5(10) 0.46
Body mass index 25.6 ± 3.9 25.4 ± 3.2 0.97
Mean arterial pressure, mm Hg 108 ± 16 106 ± 13 0.44
Laboratory results abnormal*, n (% ) 67 (53) 20 (42) 0.19
CIRS-G total score 6.7 ± 3.9 5.3 ± 2.8 < 0.05
CIRS-G severity index 1.8 ±0.6 1.5 ± 0.4 < 0.001
No. of drugs used 2.7 ± 2.5 1.4 ± 1.6 < 0.01
Polypharmacy (> 5 drugs), n (% ) 31 (24) 3(6) < 0.01
#level 1 is primary school only; level 5 is university level; * > 1 test result abnormal: sodium, 
potassium, creatinine, glucose, haemoglobin, and TSH ;+ score: 0 = independent,
1 = partially dependent, 2 = dependent
Abbreviations: MMSE = Mini-Mental State Examination; ADL = activities of daily living;
IADL = instrumental activities of daily living; CIRS-G = Cumulative Illness Rating Scale 
for geriatrics.
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Results
As listed in Table 1, age was significantly lower in the RCT group than in the con­
trol group. Gender distribution, MMSE score and the Clinical Dementia Rating scale 
score were similar in both groups. No significantly differences in disease duration, 
level of education, smoking, and alcohol intake were found between groups. In the 
control group, patients were more dependent on their caregivers for ADL and IADL, 
than patients in the RCT group. In both groups, there was a similar percentage of 
patients with gait disorders.
Physical examination revealed no differences in BMI or mean arterial pressure 
(MAP) between groups. In both groups, there was a similar percentage of patients 
with one or more abnormal laboratory tests. However, glucose levels in the control 
group were significantly higher than in the RCT group (5.7 ± 2.0 mmol/l vs. 4.9 ± 0.7 
mmol/l; p < 0.05). All other laboratory results were similar in both groups.
The CIRS-G total score and CIRS-G severity index were significantly higher in 
the control group compared to the RCT group (Table 1). Also, a moderate positive 
correlation between the CIRS-G total score and age (r = 0.39; p < 0.001) was found. 
Furthermore, when both differences in CIRS-G total score and the CIRS-G severity 
index between groups were corrected for age, they were still statistically signifi­
cantly (both p < 0.05). When analyzing the individual organ-specific categories of 
the CIRS-G, we found significant differences between groups in the categories "Heart" 
(control group 0.9 ± 1.1; RCT group 0.2 ± 0.5; p < 0.001), and "Endocrine/metabolic 
and breast" (control group 0.5 ± 0.8; RCT group 0.2 ± 0.5; p < 0.05). There were no 
significant differences between groups in the other categories.
In the control group, patients were using significantly more drugs than in the 
RCT group (Table 1).The number of prescribed drugs was positively correlated with 
the CIRS-G total score (r = 0.57; p < 0.001). Furthermore, polypharmacy was much 
more common in the control group than in the RCT group. Analysis of the different 
drug classes revealed a significantly more frequent use in the control group versus 
the RCT group of p-blockers (28% vs. 17 %; p < 0.05), and digoxin (9% vs. 0%; p < 
0.05). In the control group 19% of patients were using ACE inhibitors, 12% coumarins, 
and 19% antiplatelet agents, compared to 0% in the RCT group, since patients using 
these drugs were excluded from the trial.
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Our systematic literature search resulted in 72 RCTs (see appendix for all references) 
with AD patients testing various drugs. Nine out of 72 RCTs were multi-center trials, 
with a minimum of 2 participating sites, and a maximum of 100 sites. Most RCTs 
included only patients with probable AD according to the NINCDS-ADRDA criteria, 
however five trials also included patients with possible AD,(19-23) and two trials 
included patients with AD according to the Diagnostic and Statistical Manual of 
Mental Disorders, 4th ed. (DSM-IV) criteria.(24;25) Reviewing the inclusion criteria of 
different trials, we found different age ranges; Twenty-one out of 72 trials included 
all patients older than 50 years of age. In other trials, minimum age varied from 40 
(21;26-29) to 65 years of age,(30;31) and maximum age varied from 80 (30;31) to 95 
years of age.(32) Also, in 16 RCTs, there was no age range at all. Although all trials 
included patients with'mild to moderate AD', the lower limit of the MMSE score varied 
from 8 (33) to 16 points,(34) and the upper limit varied from 20 (35) to 30 points.(36) 
Two trials only included patients in good or excellent general health.(37;38) More 
frequently, comorbid conditions were mentioned in the exclusion criteria; In 56 out 
of 72 trials, patients with a'serious unstable illness','clinically significant concomitant 
disease; 'clinically significant coexisting medical abnormality', or'major medical ill­
ness'were excluded. Also, comedication was a frequent reason for excluding patients 
(35 out of 72 trials), especially patients using 'medication known to affect the cen­
tral nervous system; or'psychotropic medication'. Some trials excluded patients with 
specific comedication, such as cholinesterase inhibitors, or anticoagulantia.
In the majority of RCT articles, only a few baseline characteristics were 
reported, mostly to compare the placebo group with the group of patients receiving 
the study drug. Mean age of participants per group was present in all articles; Mean 
age of all participants of all RCTs was 73.4 (range 66,6 - 78.6) years of age. Also, mean 
MMSE score of participants per group was frequently available; Mean MMSE score 
of all participants of all RCTs was 19.4 (range 16.4 to 23.4) points. Other frequently 
available baseline characteristics of patients were race (36 out of 72), weight (27/72), 
disease duration (26/72), and level of education (24/72). In only 6/72 RCT articles, 
number or percentage of patients with comorbid conditions were reported.(5;39-43) 
In two articles, more specific comorbid conditions were presented: the percentage of 
patients with a cardiovascular history, and number of patients with diabetes.(36;44) 
Mean number of concomitant drugs per patient, or number and percentage of
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patients using concomitant medication were described in some articles (8/72);(5;39- 
43;45;46) 6 out of 8 articles also reported number and percentage of patients taking 
psychotropic drugs.(5;40-42;45) Three articles only gave details about number and 
percentage of patients taking several specific types of medication.(20;36;46)
Discussion
We recently reported on a randomized controlled clinical trial of indomethacin 
versus placebo that aimed to show retardation of disease progression in AD patients. 
This study failed to show any effect, although conclusions could not be drawn since 
this trial was underpowered. In the present study, we demonstrate that our eligibil­
ity criteria resulted in a cohort of participating AD patients who were younger, had 
fewer disabilities and comorbid conditions, and were taking less medication, than 
the AD patients in general who visited our memory clinic in the same period. Appar­
ently, through our strict eligibility criteria we have selected a group of patients for 
our RCT that is not representative of AD patients in our own memory clinic, most 
likely not representative of AD patients in the general population.
The relatively young age of AD patients participating in RCTs compared to 
AD patients seen in routine daily practice (mean age of our reference AD popula­
tion was 76.1 years), is a common problem seen in most trials over the past seven­
teen years. Amongst the 72 RCTs we selected from the literature, we only found ten 
studies with a mean age of participating patients > 76 years of age.(21;22;37;47-53) 
Although age in our population of AD patients was positively correlated with the 
CIRS-G scores and number of prescribed drugs, younger age also was an indepen­
dent predictor for eligibility. Therefore, we confirm the observations of two previous 
studies, that enrollment in RCTs that test drugs in AD patients is more likely to occur 
in AD patients of younger age.(8;10)
Another finding was that in the RCT group, patients had fewer ADL and IADL disabili­
ties than in the control group. This suggests that AD patients in the control group 
were functionally more impaired than patients in the RCT group, even though there 
were no significant differences between groups in score on the Clinical Dementia 
Rating scale or the MMSE.
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In view of the exclusion criteria of the indomethacin trial, our findings of less 
polypharmacy, lower medication use, less comorbidity, and also less severe comor­
bidity in the RCT group were not unexpected. Since there is not many information 
available in other RCT articles about comorbidity, one can only speculate about the 
number and severity of comorbid diseases of participating AD patients. When evalu­
ating the eligibility criteria of the selected RCTs, we found that subjects were in- or 
excluded from trials using unclear descriptions concerning comorbidity, such as 
'good to excellent general health', and'clinically significant medical conditions'. Some 
studies provided more detailed descriptions about the concomitant diseases that 
were reason for non-enrollment.Thus, this might suggest that eligible AD patients in 
other RCTs have less comorbidity, as well as less severe comorbidity. In accordance 
with our findings, other investigators found that comorbidity was an important 
reason for non-enrollment of AD patients in clinical trials.(8;10)
Specific to our RCT with indomethacin was the exclusion of patients using 
particular drugs, such as aspirin, coumarin derivatives, ACE inhibitors, and loop 
diuretics. This might explain the reduced use of other cardiovascular drugs, such 
as digoxin and p-blockers, and lower occurrence of heart disease in the RCT group. 
Subsequently, the lower rate of comorbidity of the category "Endocrine/metabolic 
and breast" in the RCT group is caused by the lower incidence of diabetes mellitus, 
an important risk factor for cardiovascular comorbidity. This is also reflected by the 
lower concentration of serum glucose in the same group of patients.
Our study was limited by the number of patients in both the RCT group and 
the control group. However, the characteristics of AD patients in our RCT group are 
comparable with other RCTs, considering the mean age of participating patients 
and strict exclusion criteria of most RCTs. Furthermore, our observed differences in 
patient characteristics between groups are in conformity with two previous studies, 
that also investigated generalizability of AD trial results, yet using different study 
methods.(8;10)
In conclusion, the external validity or generalizability of the results of our RCT with 
indomethacin, and likely also of many other RCTs involving AD patients is limited 
at best. Due to strict eligibility criteria, subgroups of AD patients are formed with 
younger age, and less comorbidity and medication use, not representative of the AD 
patients seen in routine daily practice. Thus, clinicians should take this into account,
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when prescribing AD medication. In addition, reports of RCTs should provide more 
detailed information concerning the characteristics of their participants. For future 
RCTs developing new AD therapies, we recommend less stringent eligibility criteria. 
This will also have the advantage o f a higher enrollment rate into RCTs. Less stringent 
eligibility criteria will also lead to an increased adverse event rate during drug-trials, 
giving a better reflection of the side-effects one can expect prescribing a drug to the 
AD patient in daily clinical practice.
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C h a p te r 3.1
Abstract
Background. The differentiation of Alzheimer's disease (AD) from vascular dementia 
(VaD) is hampered by clinical diagnostic criteria with disappointing sensitivity and 
specificity. The objective of this study was to investigate whether cerebrospinal fluid 
(CSF) levels of total tau protein (t-tau), amyloid P42 protein (AP42) and tau phospho- 
rylated at threonine 181 (p-tauisi) are useful biomarkers to distinguish AD patients 
from VaD patients.
Methods. We measured CSF levels of p-tauisi, AP42, and t-tau in 86 patients with a 
clinical diagnosis of AD and VaD, and 30 control subjects (NC).
Results. Optimal differentiation between AD and VaD was achieved by using the 
ratio of the CSF levels of AP42 and p-tauisi (Q Ap42/p-tau) with sensitivity, specificity, 
positive and negative predictive values all > 85%.
Conclusions. Our results support further efforts to prospectively validate the use of 
Q Ap42/p-tau as a biomarker to discriminate between AD and VaD.
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Introduction
Differentiating of Alzheimer's disease (AD) from other dementia disorders, such as 
vascular dementia (VaD), is becoming increasingly important. An accurate and early 
diagnosis is essential for appropriate support and treatm ent of dementia patients, 
as symptomatic drugs are specifically available for AD patients and neuroprotective 
drugs based on altered amyloid (3 metabolism are being developed.
The clinical diagnostic criteria currently used for AD and VaD (1;2) have dis­
appointing sensitivity and specificity,(3;4) often leading to the unequivocal diagno­
sis "mixed dementia" indicating clinical features of AD, but with multiple vascular 
lesions at brain imaging and/or cardiovascular risk factors. While AD and VaD are 
clearly different diseases (e.g. as exemplified by genetics), both seem to share vascu­
lar risk factors such as atherosclerosis and smoking.(5) Finally, AD may present with 
vascular comorbidity, which complicates the diagnostic work-up of AD patients. So, 
how to disentangle AD from vascular dementia?
Cerebrospinal fluid (CSF) analysis of amyloid 042 protein (A(342) and total tau 
(t-tau), have been advocated as diagnostic biomarkers. T-tau levels are elevated and 
A(342 levels decreased in CSF of AD patients compared to control subjects.(6;7) The 
combination o f CSF t-tau and A042 yields a highly accurate differentiation between 
AD and normal controls (sensitivity 50 - 94%; specificity 83 - 100%).(6) However, CSF 
based differentiation o f AD from VaD remains a challenge; specificity was only 48 % 
versus VaD.(8) Therefore, additional biomarkers are clearly needed. Quantification 
of hyperphosphorylated tau (p-tau) in CSF may be such a biomarker. CSF p-tauisi 
concentrations improve the discrimination of AD from dementia with Lewy bodies 
(DLB),(9) but its validity in discriminating AD from VaD has not extensively been 
studied.
In this retrospective case-control study we analyzed CSF levels of t-tau, A042 
and p-tauisi o f control subjects and patients with clinical AD and VaD, in order to 
achieve an optimal differentiation between AD and VaD.
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Methods
Patients
Patients with mild to moderate AD (n = 61) and VaD (n = 25) were selected from  
a large database containing 260 patients with cognitive impairment or dementia 
of various origins (e.g. degenerative, vascular, hereditary, inflammatory, metabolic) 
who visited our outpatient clinic between 1992 and 2004. Only patients with a diag­
nosis o f probable AD or VaD, according to accepted criteria,(1;2) were included. The 
standard diagnostic examination protocol included a complete geriatric assessment, 
neurological examination, neuropsychological testing, laboratory testing, imaging 
of the brain and a lumbar puncture. As controls (NC) we included thirty subjects 
over age 50 years who visited our outpatient clinic for various reasons but turned 
out not to suffer from a neurological disorder. Their CSF had normal leukocyte and 
erythrocyte counts, normal total protein, glucose and lactate concentrations, and no 
oligoclonal IgG bands.
CSF analysis
Lumbar punctures were performed after informed consent was obtained from the 
patients themselves and from the patient's legal representative. CSF from all partici­
pants was collected in polypropylene tubes, within 30 minutes transported to the 
adjacent laboratory at room temperature, centrifuged after routine investigations, 
and immediately aliquoted and stored at -8 0  C until analysis. Levels o f t-tau, A042 
and p-tauisi in CSF were measured using enzyme linked immunosorbent assays (all 
from Innogenetics NV, Gent, Belgium). In five AD and five VaD patients and ten con­
trol subjects, the am ount of CSF was insufficient to measure the p-tauisi concentra­
tion.
Statistical analysis
Statistical procedures were performed using GraphPad Prism (San Diego, CA) soft­
ware. All data were normally distributed; therefore, one-way ANOVA with Bonferroni's 
post hoc correction were used for multiple comparisons. Cut-off values, sensitivity 
and specificity for biomarkers in different groups were calculated using ROC curves. 
Cut-off value with the most optimal combination of sensitivity and specificity to
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discriminate between these two groups for each biomarker were calculated. Sub­
sequently, positive and negative predictive values (PPV and NPV) were calculated. 
Correlation analysis was performed by Pearson's method.
Results
Gender distribution was similar in the control (47% male, 53% female) and combined 
dementia patient groups (45% male, 55% female). The mean age of control subjects 
was significantly lower than of patients with AD and VaD (p<.001). There was no sig­
nificant age difference between patients with AD and VaD (table 1).
Table 1
Age and levels of cerebrospinal fluid markers in patients and control subjects
No. of
patients Age A [342 t-tau p-tauisi Q A (W Q A (W
(M/F) (years) (pg/m l) (pg/m l) (pg/m l) t-tau p-tau
AD 25/36 68 ± 8.8* 4 1 9 ± 128+ 613 ± 326+ 103 ± 44+ 0.9 ± 0.5+ 4.9 ± 2.7+
VaD 14/11 72 ± 8.4* 655 ± 220* 303 ± 307§ 47 ± 14§ 3.3 ± 1.9* 1 5 .9±6 .5§
NC 14/16 61 ± 8.3 869 ± 207 184 ± 89 53 ± 16 5.6 ± 2.4 16.5 ±4 .2
Notes: Mean ± SD. M = male, F = female. *p< .001, compared to  NC. +p<.001, compared to 
VaD patients and NC. *p<.001, compared to  AD patients and NC. §p<.001, 
compared to AD patients.
Mean CSF levels of A042 were significantly decreased in AD patients compared to VaD 
patients and control subjects (p<.001; tables 1 and 2) as well as in patients with VaD 
compared to control subjects (p<.001). Mean CSF levels of t-tau were significantly 
increased in AD patients compared to the other groups (p<.001). Only small, non­
significant, differences were found between the mean CSF t-tau levels of patients 
with VaD and control subjects. Mean p-tauisi levels were significantly increased in 
CSF of patients with AD compared to patients with VaD (p<.001). There were no dif­
ferences in mean CSF p-tauisi levels between patients with VaD and control subjects.
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I
A  p o s it iv e  c o rre la tio n  was o b se rve d  b e tw e e n  leve ls o f  p -tau is i a n d  t- ta u  in c o n tro ls  
(r =  0.88, p< .0001) an d  in AD  (r =  0.84, p< .0001), b u t  n o t in  VaD (r =  0.31, p=0.2).
Table 2
D iscrim inative value o f cerebrospinal f lu id  m arkers betw een groups
Groups Number of Biomarkers and cuto ff Sens Spec PPV NPV
patients values (%) (%) (%) (%)
AD vs. VaD 61 vs. 25 A [342 cu to ff = 520 pg/m l * 82 76 89 63
61 vs. 25 t-tau cu to ff = 321 pg/m l * 80 76 89 61
56 vs. 20 p-tauisi cu to ff = 68.5 pg/m l * 75 95 98 58
61 vs. 25 Q A fW t-ta u  cu to ff = 1.2 * 82 92 96 68
56 vs. 20 Q A fW p -ta u  cu to ff = 10.95 * 95 90 96 86
56 vs. 20 Q A fW p -ta u  cu to ff = 12.7 * 100 85 95 100
AD vs. NC 61 vs. 30 A [342 cu to ff = 603 pg/m l * 93 93 97 88
61 vs. 30 t-tau cu to ff = 352 pg/m l * 79 97 98 69
56 vs. 20 p-tauisi cu to ff = 68 pg/m l * 75 85 93 55
61 vs. 30 Q A fW t-ta u  cu to ff = 1.895 * 95 97 98 91
56 vs. 20 Q A fW p -ta u  cu to ff = 8.7 * 89 95 98 76
56 vs. 20 Q A fW p -ta u  cu to ff = 13.2 * 100 85 95 100
VaD vs. NC 25 vs. 30 A (342 cu to ff = 814 pg/m l * 80 67 67 80
25 vs. 30 t-tau cu to ff = 174.5 pg/m l 76 57 59 74
20 vs. 20 p-tauisi cu to ff = 45.5 pg/m l 55 70 65 61
25 vs. 30 Q A fW t-ta u  cu to ff = 3.5 * 68 87 81 76
20 vs. 20 Q A fW p -ta u  cu to ff = 14.15 55 80 73 64
Notes: Sensitivity (Sens) and specificity (Spec) to  d ifferentiate between Alzheimer's disease
(AD), vascular dementia (VaD) and contro l subjects (NC) are listed, using different
cerebrospinal flu id  markers and cu to ff values. In addition, positive predictive values (PPV) 
and negative predictive values (NPV) are shown. * p<.001.
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The Ap42/p-tauisi ratio (Q Ap42/p-tau) was significantly lower (p<.001) in patients with 
AD compared to control subjects and patients with VaD. Furthermore, the A(342/t-tau 
ratio (Q Ap42/t-tau) was significantly different in all three studied groups (tables 1 
and 2).
High sensitivity and specificity for the discrimination between AD and VaD 
was obtained at two optimal cutoff levels o f Q Ap42/p-tau (table 2). At a cutoff level 
of 12.7, sensitivity was 100% and specificity 85% with a PPV of 95% and a NPV of 
100%. At a slightly lower cutoff level (10.95), sensitivity and specificity were 95% and 
90%, respectively (PPV 96% and NPV 86%). Sensitivity and specificity o f any o f the 
other biomarkers was inferior compared to QAP42 /  p-tauisi.
Optimal separation of the AD and control group using QAp42/t-tau was achieved 
at a cut-off level of 1.895, with a sensitivity of 95% and specificity of 97%. In addition, 
very high PPV (95%) and NPV (100%) was reached with QAp42/p-tau at a cutoff level of 
13.2. Discrimination between VaD and controls using a QAp42/t-tau cut-off value of 3.5 
resulted in a combination of 68% sensitivity and 87% specificity only.
Discussion
In the present study, we found decreased CSF AP42 levels and increased CSF t-tau 
levels in patients with AD compared to VaD and normal subjects, consistent with 
the literature.(6-10) Also, the levels of AP42 and tau in patients with VaD are in line 
with another study.(8) Our main finding, however, is that the ratio of AP42 to p-tauisi 
(Q Ap42/p-tau) distinguishes between AD and VaD patients with high discriminatory 
power. Mean p-tauisi levels are doubled in the AD group, but normal in VaD, similar 
to other observations.(11; 12) Identical results were found using tau protein phos­
phorylated at serine 199 (p-taum ) and threonine 231 (p-tau23i).(9;11; 13)
Q Ap42/p-tau was significantly decreased in the AD group compared to the 
VaD group. Previously it has been reported that in AD patients a low Ap42/p-tauisi 
ratio was observed compared to healthy controls, patients with non-AD dementias 
and patients with other neurological disorders.(14) In this study we demonstrated 
that Q Ap42/p-tau has excellent diagnostic value in the differentiation of AD from  
VaD. According to a consensus report (15) a useful biomarker should be reliable,
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reproducible, and have both a sensitivity and a PPV greater than 80% for detecting 
AD and a specificity greater than 80% for distinguishing other dementias. Q A (W p -  
tau fulfills these requirements, since sensitivity, specificity, PPV and NPV are all well 
above 85%. For the discrimination between AD and NC groups, Q A (W t-ta u  may 
also be a useful biomarker, since at a cutoff level of 1.895 high sensitivity, specificity, 
PPV and NPV (each 91% or higher) were obtained. Since all patients'diagnoses were 
based on clinical criteria and not neuropathologically confirmed, im provement of 
sensitivity and specificity awaits prospective neuropathology supported studies.
A potential confounder of this study is the age-difference between patients 
and controls. However, t-tau is the only CSF biomarker known to be positively cor­
related with age (r = 0.60, p<.001).(16) Thus, differences in mean CSF t-tau levels 
between NC and AD might be smaller than described before. Since the results of our 
study do not suggestan im portant role for the analysis of t-tau in the discrimination 
of AD from VaD, and because there was no significant age-difference between AD 
and VaD, this finding does not affect our main results.
In the VaD patients group, one patient had exceptional high tau levels (1603 
pg/ml) with normal p-tauisi levels (56 pg/ml). This patient underwent the lumbar 
puncture only five weeks after he suffered from a stroke - a known cause of a tran­
sient (3-5 months) increase in CSF t-tau, but not o f p-tau.(17)
In many previous studies the focus of the application of CSF biomarkers was 
the differentiation between AD and NC. Only few addressed the truly relevant dis­
crimination between AD and other dementia disorders, particularly VaD. As recent 
studies suggested that vascular risk factors, including atherosclerosis, diabetes and 
smoking, might significantly contribute to the pathogenesis o f AD,(5;18) the con­
ventional distinction between AD and VaD has become controversial. Our study sug­
gests that a) there are biological differences between what we call AD and VaD; and 
b) Q A fW p -tau  in CSF may detect such differences in relevant clinical situations. 
The true contribution of A (W p -tau  CSF assessments to the clinical management of 
patients with late onset dementia disorders remains to be established, preferably 
through a prospective randomized masked validation study with appropriate con­
trol populations.
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Abstract
Background: Neurofilament (NF) proteins are major cytoskeletal constituents of 
neurons. Increased CSF NF levels may reflect neuronal degeneration.
Objective: To investigate the diagnostic value o f CSF NF analysis to discriminate 
in relatively young dementia patients between frontotemporal lobe degeneration 
(FTLD) and early-onset Alzheimer disease (EAD; onset < 65 years of age), and in 
elderly dementia patients between dementia with Lewy bodies (DLB) and late-onset 
AD (LAD; onset > 65 years of age).
Methods: In CSF of 28 FTLD, 37 EAD, 18 DLB, and 33 LAD patients, and 26 control 
subjects, we analysed NF light chain (NFL), phosphorylated NF heavy chain (pNFH), 
amyloid 042 protein (A042), total tau (t-tau), and tau phosphorylated at threonine 181 
(p-tauisi).
Results: CSF NFL levels were higher in FTLD patients compared to EAD patients (p < 
0.001), and diagnostic accuracy of p-tauisi and A042 analysis improved with addition 
of NFL analysis (sensitivity 86%, specificity 100%). CSF pNFH levels were elevated in 
DLB, LAD, and FTLD compared to controls (p < 0.05), however, no significant differ­
ences were found between the dementia groups.
Conclusions: In the diagnostic workup of relatively young dementia patients, CSF 
NFL levels may play a role in the discrimination between FTLD and EAD, especially in 
combination with A042 and p-tauisi analysis.
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Introduction
The clinical differentiation between Alzheimer disease (AD), frontotemporal lobar 
degeneration (FTLD) and dementia with Lewy bodies (DLB) can be achieved using 
a combination of clinical criteria, neuroimaging, and CSF biomarkers, in particular 
amyloid 042 protein (A(342), total tau (t-tau) and phosphorylated tau (p-tau).(l) How­
ever, in younger patients with incipient or mild dementia, it is often still difficult 
to discriminate between AD and FTLD. Especially so, as in patients with early-onset 
AD (EAD) focal cortical symptoms (language, praxis or executive function problems) 
and behavioural deficits, can be more prominent than memory dysfunction.(2) 
A similar challenge exists in older patients for the differentiation between AD and 
DLB, since neuropsychiatric symptoms and extrapyramidal signs are commonly seen 
in AD patients with more advanced disease.(3)
Neurofilament (NF) proteins are major constituents o f the neuronal cyto- 
skeleton. Localized in large neurons and myelinated axons, they play an im portant 
role in neuronal structure. NFs consist of three polypeptides; the light (NFL), medium  
(NFM) and heavy (NFH) subunits.(4) Increased levels of NFs in CSF may reflect neu­
ronal degeneration in neurological disease.
The analyses o f NFs in CSF of dementia patients challenged various research­
ers. CSF NFL levels were increased in AD, late-onset AD (LAD), and FTLD compared 
to controls, and tended to be increased in FTLD compared to EAD.(5-10) A positive 
correlation between CSF NFL levels and the degree of cognitive impairment was 
found in FTLD and LAD.(9)
Less is known about CSF levels of the other NF subunits. One study described 
increased CSF levels of phosphorylated NFH/M in AD compared to vascular dem en­
tia (VaD) and controls.(5) Others found elevated CSF NFH levels in AD and VaD com­
pared to controls, but no differences between FTLD and controls, or between AD, 
VaD, and FTLD.(II)
We assumed that widespread neuronal degeneration leads to elevated NF 
levels in CSF, and therefore studied CSF levels of NFL and phosphorylated NFH 
(pNFH) in patients with neurodegenerative dementias. We investigated whether 
CSF NF protein analysis helps to discriminate between FTLD and EAD in relatively
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young dementia patients, and between DLB and LAD in older dementia patients, 
and whether it has superior or additional diagnostic value compared to A042, t-tau, 
and p-tau analysis.
Methods
Patients
This retrospective study included 37 EAD (onset before or at 65 years o f age), 33 
LAD (onset after 65 years of age), 18 DLB, and 28 FTLD patients, identified through 
the CSF databases o f the Radboud University Nijmegen Medical Centre, and the VU 
Medical Centre, Amsterdam. Only patients with a probable diagnosis according to 
the accepted clinical diagnostic criteria, were included.(12-14) The standard diag­
nostic examination protocol included medical history, physical and neurological 
examination, neuropsychological testing, laboratory testing, brain imaging, and a 
lumbar puncture.
Twenty-six control subjects were included who underwent a lumbar puncture 
for various reasons, but did not have a neurological disorder.
CSF analysis
Lumbar punctures were performed after informed consent was obtained from the 
patient or the legal representative. CSF was collected in polypropylene tubes, within 
30 minutes transported to the adjacent laboratory, centrifuged after routine investi­
gations, and immediately aliquoted and stored at -80°C  until analysis.
Determination of NFL levels was performed using our previously described 
sandwich ELISA.(15) Levels of pNFH were determined using a modified version of a 
sandwich ELISA developed by others,(16) that we recently described in more detail.
(17) T-tau, A042 and p-tauisi were measured using ELISA (Innogenetics NV, Gent, Bel­
gium).
In two controls, three EAD, four LAD, and one DLB patient, the CSF amount was 
insufficient to measure either pNFH or p-tauisi concentration.
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Statistical analysis
CSF NFL and pNFH levels followed a lognormal distribution, so the statistical analysis 
was carried out on log transformed values. Tukey's method for multiple compari­
sons was used for group comparisons. In additional analyses, age and gender were 
included as covariates. For each CSF marker, the area under the receiver operating 
characteristic curve (AUC), cut-off values, sensitivity, and specificity were calculated. 
Logistic regression with backwards selection was used to derive combinations of 
CSF markers with the highest diagnostic value. For correlations Spearman's rank 
coefficient was used.
Results
Patient characteristics are listed in table 1. Our main study groups were matched 
for age. Median age of controls was significantly lower compared to LAD and DLB 
patients. Both age and gender were included in the statistical analysis, but did not 
substantially change the results.
CSF NFL levels were significantly higher in FTLD compared to EAD and controls, 
but were comparable in DLB and LAD (table 1). CSF pNFH levels were significantly 
elevated in LAD, FTLD, and DLB compared to controls (table 1). Furthermore, CSF 
pNFH levels were significantly higher in DLB than in EAD, but no differences were 
found between DLB and LAD, or between FTLD and EAD. In none of the dementia 
groups or dementia patients as a whole, a significant correlation of CSF NFL or pNFH 
with MMSE score, disease duration, or age was found.
In FTLD compared to EAD, CSF A042 was significantly higher, and t-tau and 
p-tauisi lower (table 1). CSF A042 levels were comparable in DLB and LAD. CSF levels 
of t-tau and p-tauisi in DLB were significantly lower compared to LAD.
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Table 1
Clinical characteristics and levels of CSF markers
Parameter EAD FTLD LAD DLB Controls
Age, years 61
(52-69)
63
(43-79)
76
(69-90)
72
(58-90)
60
(53-85)
No. o f patients, 
male/female
37
(15/22)
28
(20/8)
33
(13/20)
18
(13/5)
26
(12/14)
Disease 
duration, years
3.0
(1.0-10.0)
3.0
(1.0-10.0)
2.0
(0.5-7.0)
1,5
(1.0-5.0)
MMSE score 20
(6-28)
24
(3-28)
21
(9-27)
23
(2-28)
NFL, pg/m l 6.1 (n=37)1 
(0.0-40.3)
16.9 (n=28)2'3 
(0.0-76.4)
15.2 (n=33) 
(0.0-70.1)
10.4 (n=18) 
(0.0-60.4)
5.0 (n=26) 
(0.0-33.8)
pNFH,pg/m l 88 (n=36)4 
(39-205)
109 (n=28)5 
(52-373)
124 (n=29)5 
(49-398)
131 (n=18)2'3 
(71-711)
84 (n=24) 
(38-112)
A [342 , pg/m l 365 (n=37)6 
(184-703)
582 (n=28)4'7'8 
(202-1408)
419 (n=33)6 
(197-873)
444 (n=18)1 
(176-784)
-
t-tau, pg/m l 565 (n=37)1'4 
(173-1946)
362 (n=28)3'10 
(115-983)
647 (n=33)1'9 
(178-2400)
270 (n=18)3'8 
(105-961)
-
p-tauisi, pg/m l 86 (n=35)6'9 
(47-250)
51 (n=28)7'8 
(24-132)
89 (n=33)6'9 
(31-254)
58 (n=17)7'8 
(32-89)
-
Values are expressed as medians (range). ’ p<0.01, compared to  FTLD; 2p<0.001, compared 
to  controls; 3p<0.01, compared to  EAD; 4p<0.01, compared to DLB; 5p<0.05, compared to 
controls; 6p<0.001, compared to  FTLD; 7p<0.001, compared to  EAD; 8p<0.001, compared to 
LAD; 9p<0.001, compared to  DLB; 10p<0.01, compared to  LAD.
When discriminating between FTLD and EAD using CSF NFL levels, sensitivity was 
82%, and specificity 70% (table 2; AUC = 0.80). This discriminative value was com­
parable with A042 and p-tauisi. However, a combination of CSF levels of A042 and 
p-tauisi improved sensitivity and specificity significantly compared to p-tauisi alone 
(AUC = 0.89), and even more so when CSF NFL levels were added (AUC = 0.92). CSF 
NFH levels did not offer additional diagnostic value.
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Table 2
Discriminative value of CSF markers between patient groups
FTLD versus EAD DLB versus LAD
CSF markers AUC Cut off 
(pg/m l)
Sens
(%)
Spec
(%)
AUC Cut o ff 
(pg/m l)
Sens
(%)
Spec
(%)
NFL 0.80 6.7 82 70 0.53 6.0 33 82
pNFH 0.62 129 46 78 0.55 84.8 89 28
A [342 0.78 488 64 92 0.49 590 89 21
t-tau 0.71 420 68 70 0.82 361 72 88
p-tauisi 0.81 53.0 57 97 0.86 68.7 82 85
A (342 + p-tauisi 0.89* -8.11 75 94 0.88 22.53 82 94
A (342 + p-tauisi + NFL 0.92** -4.12 86 100 0.88 23.04 82 94
AUC, area under the curve; Sens, sensitivity; Spec, specificity.
*statistically significant im provem ent versus p-tauisi alone;
"s ta tis tic a lly  significant im provem ent versus p-tauisi and Afk? com bination
The discrim inant formulas for the com bined markers a re :1 2.6*1 n(ptauisi)-3.0*ln(A(342);
2 3.5*ln(ptauisi)-2.3*ln(A(342)-2.0*ln(NFL);3 3.8*ln(ptauisi)+1.0*ln(A(342);
4 3.9*1 n(ptauisi)+1.0*ln(A(342)+0.1*ln(NFL).
When differentiating DLB from LAD, the combination of CSF p-tauisi and A042 per­
formed best (table 2). CSF NFL or pNFH measurements did not have additional dis­
criminative value.
Discussion
In FTLD, CSF NFL levels were increased, consistent with other studies,(6;9;10) and 
the analysis had additional diagnostic value in the differentiation of FTLD from  
EAD, in combination with p-tauisi and A042. In contrast to a recent study, we also 
found elevated CSF pNFH levels in FTLD.(11) Thus, perhaps not only tau, but also 
other cytoskeleton proteins are involved in the pathophysiology o f FTLD.(9;10) The 
heterogeneity in the underlying pathology of FTLD, however, makes it difficult to
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disentangle the exact function of NFs in this process.(18) It has been hypothesised 
that NFs are either defective or overexpressed in FTLD and aggregate intracellularly, 
disrupting the cytoskeleton and cell integrity, causing cytoskeleton protein leakage 
into theCSF, and premature cell death.(9) Since only CSF levels of NFL and pNFH, but 
not tau, are increased, this suggests that NFs are overexpressed in neurons, and that 
these neurons are selectively vulnerable in FTLD.
In DLB compared to LAD, CSF levels of NFL and pNFH had no discriminative 
value. Nevertheless, our observation of elevated pNFH levels in DLB contributes 
to the emerging picture of abnormal CSF protein composition in degenerative 
dementias. Since CSF NFL levels were not increased in DLB, the difference in CSF NF 
and pNFH composition compared to FTLD suggests differences in the underlying 
pathophysiologic mechanism of these disorders. There is evidence that phospho- 
rylated and nonphosphorylated NFs accumulate in Lewy bodies. Also, an increased 
number of cortical NF-containing neurons was observed in DLB, compared to AD 
and controls,(19) which apparently does not lead to increased CSF NFL concentra­
tions. Altogether this suggests that in DLB, AD, and FTLD, different cortical neuronal 
populations are affected, and different subsets o f NFs are involved.
In LAD, we observed elevated CSF pNFH levels, corroborating earlier obser- 
vations.(11) We could not confirm previous reports that showed increased CSF NFL 
levels in AD.(5-9;20) Unanticipated, a nonsignificant trend of increased CSF NFL and 
pNFH levels in LAD compared to EAD was found, consistent with another study 
describing elevated CSF NFL levels in LAD compared to EAD.(9) Since an association 
between the presence of white matter changes and increased CSF NFL was previously 
described,(8) and white matter lesions are more common in LAD than EAD patients, 
this might explain our observation.
The implications o f our study may be limited because of the relatively small 
numbers o f patients. This, together with the absence of postmortem verification, 
might explain the considerable dispersion in CSF NFL and pNFH levels found in each 
patient group. Nevertheless, compared to previous studies on NFs in CSF, our FTLD 
group is the largest, and our DLB group is the first ever described. Also, the absence 
of postmortem verification applies to many studies on biomarkers in dementia. To 
compensate for the lack of postmortem diagnoses, we conducted an extensive diag­
nostic examination protocol.
94
CSF n e u ro f i la m e n t  p ro te in s  In th e  d if fe re n t ia l d ia g n o s is  o f  d e m e n tia
We conclude that measurement o f CSF NFL levels can play a role in the diagnos­
tic workup of patients with FTLD and EAD, particularly in combination with A042 and 
p-tauisi analysis. The contribution of CSF NFL analysis to the clinical management of 
these relatively young dementia patients will have to be established through larger 
prospective randomized masked validation studies. In addition, ongoing research 
may shed more light on pathophysiological mechanisms explaining the observed 
elevated CSF levels of NFL in FTLD, and pNFH in FTLD, LAD, and DLB.
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Abstract
In this comprehensive review we summarize the current state-of-the-art of neuro­
chemical biomarkers for Alzheimer's disease. Predominantly these biomarkers com­
prise cerebrospinal fluid biomarkers directly related to the pathofysiology o f this 
disorder (such as amyloid (3 protein, tau protein). We particularly pay attention to 
the innovations in this area that have been made in technological aspects during 
the past 5 years (e.g. multiplex analysis of biomarkers, proteomics), to the discovery 
of novel, potential biomarkers (e.g amyloid (3 oligomers, isoprostanes), and to the 
extension of this research towards identification o f biomarkers in plasma.
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Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accu­
mulation of extracellular senile plaques and intracellular neurofibrillary tangles (NFTs) 
in cortical and limbic brain regions (1;2). Until now, a definitive diagnosis of Alzheim­
er's disease can only be made after postmortem examination of the patient. During 
life only a "probable AD"diagnosis is possible, as based on clinical features and the 
results of neurological and neuropsychological testing, added by the exclusion of 
other dementias, in particular frontotemporal lobe degeneration (FTLD), dementia 
with Lewy bodies (DLB), and vascular dementia (VaD). An accurate and early diag­
nosis is essential for appropriate support and treatm ent o f dementia patients, since 
drugs for the symptomatic treatm ent o f AD are currently available and drugs that 
may slow or halt the progression o f the disease are being developed.
The clinical diagnostic criteria currently used for dementia disorders (NINCDS- 
ADRDA criteria for AD, Lund and Manchester criteria for FTLD, Consensus guidelines 
for DLB and NINDS-AIREN criteria for VaD (3-6)) were initially developed for research 
purposes. The accuracy of these criteria was then examined in several clinicopatho- 
logical studies. It was established that a clinical diagnosis o f probable AD could be 
achieved with a sensitivity of 41% to 93% and a specificity varying between 23% and 
100% (7-9). Similar studies yielded 85% sensitivity and 97% specificity for FTLD (9), 57 
to 78% sensitivity and 64 to 100% specificity for probable DLB (9-11), and 20% sen­
sitivity and 93% specificity for probable VaD (12). Clearly, to improve upon these less 
than perfect characteristics, the introduction of additional discriminating diagnostic 
markers (biomarkers) is needed to improve our diagnostic accuracy. Analysis of vari­
ous brain specific proteins in cerebrospinal fluid (CSF), i.e. biomarkers closest to the 
brain's chemical composition, have already proven to be very sensitive and specific 
in preliminary validation studies (13-16).
In this review, we summarize the studies reporting on CSF biomarkers in AD 
and other dementias. Furthermore, we particularly pay attention to the techno­
logical innovations in this area during the past five years, to the discovery of novel, 
potential biomarkers, and to the extension o f this research towards identification of 
biomarkers in plasma.
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Cerebrospinal fluid A042, t-tau and p-tau
In this paragraph we summarize the abundant literature that has been published 
over the past ten years on this topic. For a more extensive review of this topic we 
refer to previously published reviews (17-20).
A(342, t-tau and p-tau in the nosological classification of dementia disorders
The characteristic neuropathological findings in AD brains are senile plaques, NFTs, 
and degeneration o f neurons and their synapses. The major component of senile 
plaques is amyloid (3 protein (AP), while tau protein, particularly hyperphosphory- 
lated tau, is the primary constituent of NFTs. Therefore, levels of both proteins in 
CSF of dementia patients have been thoroughly investigated as potential diagnostic 
biomarkers.
Significantly decreased concentrations of A042 in CSF were found in AD patients 
compared to controls (15;21 -27), to patients withVaD (25), and to patients with FTLD 
(27) (Table 1). Mean CSF A042 levels were decreased in patients with DLB compared 
to normal subjects, but no differences were found between the AD and the DLB 
group (26). It should be noted, however, that in none of these studies a clear-cut 
discrimination between the various forms of dementia could be achieved.
The level of CSF total tau protein (t-tau), which includes both normal and hyper- 
phosphorylated tau (p-tau), seems to correlate with the number o f NFTs in AD post­
mortem brains (28). Mean CSF t-tau levels were found significantly elevated in AD 
patients as compared to control subjects (15;23-27;29-35), DLB patients (25;26;32), 
FTLD patients (27;30), and patients with VaD (25;30;33) (Table 1). In FTLD patients, 
however, a large variation in CSF t-tau levels is described in different studies, vary­
ing from non-detectable to significantly elevated (27;30;34;36-41).This is most likely 
due to the fact that FTLD comprises at least three neuropathologically different sub- 
types, that is with tau deposition (Pick's disease and familiar FTLD with tau pathol­
ogy, both approximately 20% of FTLD patients) or w ithout tau pathology (60% of 
FTLD patients) (42;43). Some of these tau-negative FTLD patients are recently linked 
to mutations in the progranulin gene (44;45). Furthermore, the surprisingly low CSF 
tau levels found in one study (40) can also be explained by methodological issues 
regarding appropriate sample handling (see also section 1c) (41).
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Table 1
Overview of CSF findings for A042, t-tau, and p-tauisi in the most common 
dementia disorders
Groups I Aß42 I t-tau | p-tauisi
Normal ageing N N N
Alzheimer's disease 4-4- t t t t
Dementia w ith  Lewy bodies 4' N / ( t ) N
Frontotemporal lobar degeneration N /  (4-) variable N /  t
Vascular dementia N /  (4-) N /  t N
Creutzfeldt-Jakob disease 4' t t t N
CSF concentration: N = normal; 'Is = increased; 4- = decreased.
A [342 = amyloid (342 protein; t-tau = to ta l tau; p-tauisi = tau phosphorylated at threonine 181.
P-tau, also measurable in CSF, appeared another promising biomarker in view of the 
neuropathological findings in AD. Tau can be phosphorylated at various sites, cor­
relating with three stages of neurofibrillary tangle formation: 1) pre-neurofibrillary 
tangles (tau phosphorylated at threonine 231; p-tau23i); 2) intra-neuronal neuro­
fibrillary tangles (tau phosphorylated a tthreon inel 81; p-tauisi);and 3) extra-neuronal 
neurofibrillary tangles (tau phosphorylated at serine 199; p-taui9<>) (46). Measure­
ment of p-tau23i in CSF improved discrimination of AD from FTLD (47) (Table 1). 
and measurement o f p-tauisi levels enhanced the discrimination of AD from DLB 
(48-50).
Subsequently, many studies followed that investigated all the above men­
tioned CSF markers in order to find the most optimal combination of markers for the 
discrimination between different dementias. The combination of CSF t-tau and A042 
concentrations yielded a sensitivity varying between 81 and 94 percent and a speci­
ficity varying between 79 and 95 percent when differentiating between AD patients 
and normal controls (15;24;25;27;32), mostly established with the (imperfect) clini­
cal diagnoses as the golden standard. However, the clinical challenge to distinguish 
AD from specific other dementia disorders still remained. The specificities for the 
distinction between AD and DLB, VaD, and FTD, were 67 ,48 , and 85 percent respec­
tively (25;27). The A fW p-tauisi ratio was found to be a good discriminator between
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AD and VaD (sensitivity, specificity, negative and positive predictive values all > 85%) 
(51). AD and DLB could be differentiated by the t-tau/p-tauisi ratio, but values still 
overlapped markedly (52). To facilitate simultaneous measurement o f these three 
biomarkers, a new technique has been developed (see section 1 d.).
CSF A042, t-tau, and p-tau analysis can also be useful in the discrimination 
between sporadic Creutzfeldt-Jakob disease (CJD) and other dementias. CJD is char­
acterized by progressive dementia, pyramidal dysfunction, myoclonus, extrapyrami- 
dal signs, visual symptoms, and ataxia, but the differentiation from other dementia's, 
especially AD and FTLD, can be difficult very early in the course of CJD. In CSF of CJD 
patients, very high levels of t-tau were found. Using a cut-off value of 1300 pg/ml 
a diagnostic sensitivity o f 94% with 90% specificity was achieved, with a positive 
predictive value of 92% (53). In another study a CSF t-tau cut-off value of 2131 pg/ 
ml resulted in a sensitivity of 93% and specificity of 100% for the discrimination 
between CJD and AD (54). In accordance with the absence of hyperphosphorylation 
of tau proteins and NFTs in brains of CJD patients, relatively low CSF p-tau concen­
trations (< 85 ng/L) were found (55). Furthermore, the CSF p-tau/t-tau ratio was also 
found to be a good discriminator; CJD patients could be differentiated from AD and 
FTLD (55;56). CSF A042 levels were decreased in CJD patients, but to a similar degree 
as in AD patients (54;57). The immunodetection of 14-3-3 proteins in CSF has also 
shown high sensitivity and specificity for CJD (53;58;59). However, further research 
revealed false negative results in some typical, autopsy proven CJD cases (59;60), 
and false positive results in patients with other dementias, including AD, DLB, FTD, 
and VaD (61;62).The concentrations of neuron-specific enolase (NSE) and S-100 pro­
tein are also elevated in CSF of CJD patients (63-66). Thus, CJD can be discriminated 
from other dementias by the combined analysis of A042, t-tau, p-tauisi, 14-3-3 pro­
tein, NSE and S-100 protein.
Postmortem verification studies
Although the neuropathological diagnosis of different dementias is considered the 
"golden standard", there are only a few studies that used autopsy-confirmed diagno­
ses as such. Two studies included only patients with autopsy-confirmed dementias. 
The first investigated the correlation of 106 antemortem CSF t-tau and A042 levels 
with postmortem dementia diagnoses, and confirmed the earlier observations that
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elevated t-tau levels and reduced A042 levels in CSF are associated with AD pathol­
ogy, and can help discriminate AD from other dementias (37). Interestingly, there 
were also a few patients in this study who met the clinical and pathological criteria 
for AD, but had CSF t-tau levels below a pre-defined cutoff value. In the second and 
recently published study, levels of A042, t-tau and p-tauisi were determined in CSF 
samples from 100 autopsy-confirmed dementia and 100 control subjects. AD was 
optimally discriminated from non-AD dementias using p-tauisi and A042 (sensitivity 
80%, specificity 93%) (67).
Other studies included a few autopsy confirmed patients within their larger 
group of dementia patients. Based on CSF levels o f t-tau and A042, 12 out of 13 
patients with postmortem diagnoses could be correctly classified as having AD or 
not in one study (15). In two other studies, a small number of autopsy confirmed 
dementia patients were included, but unfortunately mean CSF tau and A042 levels of 
these subgroups of AD and FTD patients were not described (17;40).
Thus, information about CSF biomarkers in autopsy confirmed AD patients 
is relatively limited, but generally confirms the observation in the more numerous 
studies based on clinical diagnosis of dementia syndromes. More studies will likely 
follow on this issue, also including more patients with autopsy confirmed dementia 
diagnoses other than AD. However, it is to be expected that the generally accepted 
view of CSF A042, t-tau and p-tauisi will not dramatically change with these additional 
studies. Ideally, we still need the conformation of the validation of CSF biomarkers 
against a randomly selected postmortem sample, in which referral and selection 
bias, possibly still im portant in the studies that have been performed up to now, has 
been excluded.
Effect of processing and storage conditions, and reference values
Several pre-analytical factors will have to be considered for correct and reliable anal­
ysis of A042, t-tau and p-tauisi. It was reported that sampling of CSF in tubes made 
of glass or polystyrene leads to up to 30% reduced concentrations of A042 relative to 
collection in polypropylene tubes (68) .This was confirmed in one subsequent study 
(69) that showed that various A(3 peptides were up to 30% decreased in polystyrene 
tubes, the t-tau concentration decreased by 15%, while the p-tauisi concentration 
remained unaffected. Sampling in polycarbonate or modified polystyrene (polysty- 
rene/acetonitrile mixture) did not affect results (69).
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Prolonged storage of CSF at-80°C  does not affect A042 ort-tau concentrations (70;71). 
CSF tau protein is even stable at up to 18°C for more than two weeks. A042 concentra­
tions, however, may decrease by 20% during the first two days when stored at 4°C 
or 18°C while thereafter they remain stable (71). In contrast, in another study a small 
increase in the A042 concentration was demonstrated after storage for 24 hours at 
room temperature (72). We did not observe any effects on p-tauisi concentrations 
(unpublished data) when CSF was stored for 24 hours at -20°C, 4°C or 20°C. Neither 
did a single freeze/thaw cycle affect A042 or t-tau concentrations. A042 concentra­
tions did decrease, however, by 20% after multiple freeze/thaw cycles, whereas t-tau 
concentrations remain stable (71). We did not observe any effects on p-tauisi con­
centrations after a single freeze-thaw cycle (unpublished data). Furthermore, blood 
contamination of CSF samples leads to reduced concentrations of t-tau, p-tauisi and 
A042 (own observations). Finally, we did not find any indication for a lumbar-ventric- 
ular gradient in the concentrations o f t-tau, p-tauisi and A042. Recently, however, it 
was reported that the concentrations of A(3 may follow diurnal fluctuations (73), sug­
gesting the need for standardized sampling procedures.
In summary, the following procedures are advised when analyzing t-tau, 
p-tauisi and A(3i -42 in CSF: 1) CSF should be collected and stored in polypropyl­
ene tubes. 2) For optimal analysis, CSF samples should be centrifuged, aliquoted 
and stored at -80°C  as soon as possible after withdrawal, although the effects of 
short-term storage at higher temperatures on the analytical results are minimal.
3) Samples contaminated by blood or hemolytic CSF should not be used for analysis.
4) Repeated freeze/thawing of CSF should be avoided. 5) Aliquots from any of the 
CSF fractions that are collected can be used; there is no need for a standardization 
of the volume to be analyzed. 6) Because of possible diurnal fluctuations, CSF w ith­
drawal should be performed at a standardized time point o f the day, but the initial 
observations on this matter await confirmation.
Studies aimed at analyzing and comparing the performance of different labo­
ratories using the same tests for analysis of A042, t-tau and p-tauisi have been rarely 
reported. In a study with 13 laboratories testing three CSF samples, coefficients of 
variation (CV) varied from 8.5% to 10.8% (p-tauisi), 8.5% to 30% (t-tau) and 20 to 60%  
(AP42) for users o f the Innogenetics assays (Innogenetics NV, Ghent, Belgium) (74). 
In a study with 14 participating laboratories testing a single CSF sample CV's varied
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from 26 to 29% for these three assays (75). This implies that, as long as a uniform  
standardization of (pre-)analytical procedures has not been defined, inter-labora- 
tory comparisons of test results are possible to a limited extent only. However, since 
intra-assay CV's are low (< 8.3% for all three assays as determined in our laboratory 
(76)), stable and reproducible results can be produced by one and the same labora­
tory over time. Finally, given the high inter-laboratory CV's, each laboratory should 
establish their own reference ranges.
The reference values for CSF t-tau and A042 levels using sandwich ELISAs by 
Innogenetics were established in 231 healthy individuals, 21-93  years of age, with a 
Mini-Mental State Examination score of 28 or above (77). Since a positive correlation 
was found between age and CSF t-tau, separate reference values for different age 
groups were established: < 300 ng/L (21-50 years), < 450 ng/L (51-70 years), and
< 500 ng/L (71-93 years). The reference value for CSF-AP42 was set to > 500 ng/L 
(Table 2). In addition, there was no correlation found between blood-CSF barrier 
(dys)function and levels of t-tau or A042 in CSF. In our own laboratory we established 
reference ranges with the Innogenetics assays that are largely in line with these data 
(AP42: > 400 ng/L (< 15 years), > 500 ng/L (> 15 years); t-tau: < 300 ng/L (< 50 years),
< 350 ng/L (> 50 years); p-tauisi: < 85 ng/L (> 15 years)) (Table 2). For reasons men­
tioned above, these reference ranges may not be universally applicable.
Table 2
Reference values for A042, t-tau, and p-tauisi in cerebrospinal fluid
CSF biomarker Age
(years)
Sjogren et al. (77) 
(ng/L)
Our laboratory 
(ng/L)
A(342 < 15 >400
21 - 93 > 500 > 500
t-tau 21 - 50 < 300 < 300
51 -7 0 <450 < 350
71 - 93 < 500 < 350
p-tauisi > 15 < 85
A [342 = amyloid (342 protein; t-tau = total tau; p-tauisi = tau phosphorylated at threonine 181.
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Multiplex analysis of A(342, t-tau and p-tauisi
Robust analysis of A042, t-tau and p-tauisi should enhance their usefulness in AD 
diagnosis. As noted above, analysis of these three biomarkers by ELISA may lead to 
relatively high inter-laboratory variation. The recent development of assays based 
on the xMAP technology may possibly solve this issue. The Luminex xMAP technol­
ogy has several advantages over conventional ELISA. It involves coupling of capture 
antibodies to microspheres (with a unique color code) and fluorescent dye-labeled 
detecting antibodies. By using a flow cytometry-based detector, multiple analytes 
can be detected simultaneously. Compared with ELISA, xMAP technology requires 
less total assay time, fewer procedural steps, and a smaller sample volume. It has a 
higher reproducibility than ELISA, because the result of each analysis is the mean of 
multiple (typical 50-100) readings. xMAP assays to quantify A042, t-tau, and p-tauisi 
in CSF, together with test characteristics for calibration, precision, and specificity 
have been recently described (78). Inter-assay CV's for the three analytes are all < 8.4 
to 10% (76;78). In contrast to what has been suggested by others (78), we observed 
that a single correction factor cannot be applied to recalculate xMAP results into 
ELISA results (or vice versa), suggesting that the introduction of xMAP assays should 
be accompanied by a complete method validation, including a re-establishment of 
reference ranges specific for this assay which are different from those used for the 
ELISAs (76). However, both ELISA and xMAP assays had a comparable analytical per­
formance to differentiate AD patients from either controls or VaD patients (76). In 
another recent, multi-center study, it was demonstrated that the xMAP assays for 
A042, t-tau, and p-tauisi may identify patients with mild cognitive impairment (MCI) 
that convert to AD among a population of MCI patients, just as has been described 
for the ELISA assays (79).
Relation with disease severity
In many studies, the correlation between disease severity and CSF levels of A042, 
t-tau, and p-tau was investigated. The results were not unanimous. Some studies 
did find a correlation between one or more CSF biomarkers and disease severity 
(13;15;80-82), while many others did not (14;29;30;83-86). Also, remarkably stable 
CSF A042, t-tau, and p-tau concentrations over a 6-month period were found in indi­
vidual AD patients (87). In agreement with these latter findings, decreased CSF A042
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levels and increased t-tau levels were already found very early in progression of AD, 
thus trading the correlation with disease progression for better diagnostic sensitiv­
ity. In line with this, in MCI patients, these biomarkers were able to predict progres­
sion to AD (88-92). Similarly, marked increases in CSF p-tau levels were found in MCI 
cases who at follow-up progressed to AD, compared to stable MCI cases (92;93). 
Similar results were achieved using the xMAP technology (94). The t-tau/A(Î42 ratio or 
the p-tauisi/Ap42 ratio in CSF can also be used to predict conversion from cognitively 
normal to AD (95).
Since it is thought that Alzheimer pathology starts at least 20 to 30 years 
before the clinical onset o f the disease (96), one could speculate that altered CSF 
levels o f the above mentioned biomarkers are present even before cognitive dys­
function begins. Thus, when drugs with potential effects on the progression of AD 
reach the clinical phase, CSF diagnostics would be helpful in identifying people at 
risk of developing AD.
Discovery of novel biomarkers by proteomics
Technological advances over the past few years, and the recognition that it is indeed 
possible to define biomarkers in CSF for AD, have sparked the interest in proteomics 
techniques to identify such new biomarkers. Several approaches have been followed, 
either based on separate technologies, e.g hypothesis-free two-dimensional gel- 
electrophoresis (2D-GE) combined with matrix-assisted laser desorption/ionization 
tim e-of flight (MALDI-TOF), mass spectrometry (MS) or surface enhanced laser des­
orption/ionization (SELDI-) TOF MS, or application of these techniques to unbiased 
proteomics approaches (protein profiling without any type of preselection for bio­
markers), or procedures with enrichment for specific protein species (e.g. SELDI-TOF 
with antibody capture).
Unbiased approaches; 2D-GE and MALDI-TOF analysis
Because of the extensive improvement in the techniques to perform 2D-GE and the 
increased possibilities to identify proteins by MS, the number o f studies aimed at 
the identification of biomarkers in CSF by using this technique has grown steadily.
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In 2D-GE proteins are separated in the first dimension on the basis of their pi by iso­
electric focusing (IEF) and in the second dimension by SDS-PAGE according to their 
molecular weight. Specific protein spots can be picked out the gel, trypsin-digested 
and the resulting peptides are analyzed by (MALDI-TOF) MS or nano-LC-MS. Numer­
ous technical papers have been published in which technical advances and methods 
have been described to pretreat or enrich CSF samples for low-abundant proteins. 
Several pre-treatment strategies (protein precipitation, column filtration, removal of 
albumin and immunoglobulins) may improve 2D-GE patterns (97), leading to large 
databases of CSF proteins (98). The use of liquid IEF (instead of solid-phase IEF) fol­
lowed by SDS-PAGE and MS analysis allows for identification of proteins in the vari­
ous fractions, but mainly high-abundant proteins are identified and large volumes 
of CSF are needed (99). An extra IEF step may resolve less abundant proteins (100). 
Irrespective the exact technology that has been applied, all the variants on the  
concept of 2D-GE have led to the definition o f combinations o f multiple proteins 
-  ranging from 5 to 25 in number -  that may discriminate AD from non-AD CSF by 
2D-GE (see a recent review for a comprehensive overview (101)) (102-104). Most 
studies described alterations in abundant, mostly blood-derived proteins, that are 
often w ithout any relation to the presumed pathophysiology of AD, and that are 
usually not confirmed by alternative techniques (e.g. ELISA) or in independent stud­
ies (105;106). One recent study, however, in which 2D-GE analysis of plasma proteins 
combined with LC-MS/MS characterization demonstrated increased concentrations 
of complement factor H and a2-macroglobulin in AD (107). However, although the 
findings from the 2D-GE studies indicated a large quantitative difference in the levels 
of these proteins, after confirmation by ELISA these differences appeared much 
smaller resulting in sensitivity, specificity and negative/positive predictive values all
< 68%. Furthermore, the use of such combinations of protein markers relative to the 
analysis of A042, t-tau and p-tauisi has notyet been studied. Given the advances that 
have been achieved so far, it is unlikely that a laborious and relatively insensitive 
experimental approach such as 2D-GE combined with MS analysis, will ever reach 
clinical application, or lead to discovery of novel biomarkers for AD.
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SELDI-TOF MS
SELDI-TOF is a technique that probably has more potential than 2D-GE/MS to iden­
tify novel biomarkers, since it allows not only for an unbiased approach in the search 
for biomarkers, but also for more specific identification of proteins e.g. by applying 
pre-selection with antibodies.
In a small study using CSF of 9 AD patients and 10 controls, four proteins 
(cystatin C, two p2-microglobulin isoforms, one unidentified protein) were over­
expressed and one protein (VGF polypeptide) was under-expressed in AD CSF (108). 
In a somewhat larger study (16 FTLD and 12 controls) (109), five proteins were 
increased in FTLD and five others were decreased. Among the increased proteins 
were transthyretin and S-cysteinylated transthyretin, and among the decreased pro­
teins were VGF, truncated cystatin C (amino acids 1-8 deleted) and a chromogranin 
B fragment. Finally, in a recent comparison with 65 AD and 44 control samples, a 
model with five proteins (decreased levels in AD: cystatin C and an unknown 4.0 
kDa protein, increased levels in AD: truncated cystatin C, C3a anaphylatoxin des-Arg, 
A ( 3 i -4o) together with t-tau and A ( 3 i -42 analysis optimally discriminated these groups 
(110). Also in this study, decreased concentrations of VGF were found. In general, rela­
tively high-abundant proteins are selected in theSELDI procedures, th a t- in  combina­
tion with t-tau and AP1-42, may provide a useful panel of markers to discriminate either 
AD or FTLD from controls. Somewhat worryingly, several of the proteins identified in 
these studies and suggested as biomarkers for AD or FTLD (e.g. (truncated) cystatin 
C, VGF, transthyretin) have also been nominated as biomarkers for amyotrophic 
lateral sclerosis (111;112), schizophrenia (113), or multiple sclerosis (114), suggesting 
that several of the proteins (or combinations thereof) identified as biomarkers for a 
specific disease by SELDI-TOF, are more likely to be reflections of ongoing general­
ized neurodegeneration rather than related to specific pathophysiological disease 
processes. Alternatively, they may be selectively identified under the applied techni­
cal conditions. Obviously, larger validation studies with more clinical subgroups, and 
validation of the data by independent techniques, need to be performed to assess 
the clinical validity of these findings.
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A(i peptidom ics identified by SELDI-TOF or gel electrophoresis
Most studies aimed at the identification o f Ap in CSF, have focused on APi «  or AP1-40. 
However, several other studies suggested the presence o f numerous other Ap spe­
cies in the CSF, i.e. N-terminally or C-terminally truncated species, and Ap peptides 
with an elongated C-terminus. Such peptides have been identified by SELDI-TOF or 
urea-based gel electrophoresis. Moreover, evidence is accumulating that dimeric or 
higher assembled forms of Ap peptides may circulate in the CSF.
By coating the SELDI chip with an anti-Ap capture antibody, it is possible to 
employ SELDI-TOF to specifically detect these alternative Ap species present in the 
CSF. In a study with a small number of AD (n=10) and control patients (n=9), it was 
found that Ap peptides other than AP1-42 or AP1-40 are present in CSF at abnormal 
concentrations in AD compared to controls. These new Ap peptides could fit with 
the following sequences: AP3-44 (decreased in AD), AP3-47 (increased in AD) and a 
possible dimer o f Ap (decreased in AD) (115). Ap peptides starting at residue 1 and 
ending at residues 37 to 40 were present in AD and control CSF at equal concen­
trations. In addition to these peptides, the same research group as well as another 
group published the identification of many different truncated Ap peptides in the 
CSF (116; 117), of which AP1-38 was reported to be decreased in AD compared to con­
trols in the one study (116), but not in the other (117). Recently, we performed a 
similar study with CSF of 18 AD, 20 VaD and 17 controls patients (unpublished obser­
vations). We observed decreased concentrations of AP1-37, AP1-38, AP1-39 and AP1-40 in 
AD compared to either VaD or controls. Furthermore, we found decreased levels of 
A P  1-33, AP1-34, several oxidized Ap peptides and possible dimeric and trimeric forms 
of Ap in AD vs. VaD or controls. We uncovered preliminary evidence that a possible 
dimeric AP1-38 peptide was decreased in both AD and VaD. These findings of altered 
concentrations of assembled forms of Ap in CSF are in line with the observation 
that the concentrations of so-called Ap-derived diffusible ligands ("oligomers") are 
altered in AD CSF compared to controls (118).
Urea-based gel electrophoresis allowed a good separation o f Ap peptides of 
various lengths (119). By using the AP1-42/A P 1-37 ratio, AD patients (n=23) could be 
differentiated from DLB (n=21), idiopathic Parkinson's disease (n=21) or controls 
(n=23) (120). However, a disadvantage of this method may be that quantification of 
Ap peptides is likely subject to larger analytical variation than, for example, specific
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ELISAs. A combination of immunoprécipitation with anti-Ap antibodies and subse­
quent MALDI-TOF yielded a significant increase in APi-ie in AD CSF and, in combina­
tion with APi-42, APi-33, and AP1-39, may distinguish AD from control CSF (121).
The results of these various studies suggest that several of the identified Ap 
peptides or aggregated forms o f Ap are worth to be further studied as a potential 
biomarker for AD, in particular by using specific quantification techniques (e.g ELISA), 
and in larger patient cohorts (also including other dementia forms).
Other potential CSF biomarkers
In the past years, numerous potential CSF biomarkers for AD and other dem en­
tias have been studied, e.g. amyloid precursor protein (APP), apolipoprotein E, 
al-antichym otrypsin, C-reactive protein, complement C lq , homocysteine, 3-nitro- 
tyrosine, neuronal thread protein, NSE, glial fibrillary acidic protein, S-100B protein, 
ubiquitin, and growth-associated protein-43 [for details, see other reviews ( 19; 122- 
124)]. However, none of these proteins and metabolites appeared useful as biomark­
ers in clinical practice, because of conflicting results between different studies, or
Table 3
Potential CSF biomarkers for dementia
Group Potential CSF biomarker Reference no.
Isoprostanes F2-isoprostane (4 0 ,1 2 5 - 127)
Cytokines IL-1 ß (123,128)
IL-6 (123, 128,129)
IL-12 (130)
IL-15 (131)
TNF-alpha (123,128)
Neurofilaments NFL (1 3 2 - 138)
NFH/M (132)
NFH (138,139)
Aß oligomers (1 1 8 ,1 4 0 - 142)
Enzymes BACE-1 (143)
ACE (144,145)
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because of an inferior capacity to discriminate between different dementias com­
pared to A042, t-tau or p-tauisi. More recently studied potential CSF biomarkers are 
described below (see also table 3).
Isoprostanes
Oxidative damage may play a role in the pathogenesis o f AD. Isoprostanes are exclu­
sive products of free-radical-mediated peroxidation o f arachidonic acid. Levels of 
isoprostanes were found markedly elevated in both frontal and temporal cortex of 
AD brains, but notin  the corresponding areas of FTLD brains and controls (125; 126). 
F2-isoprostanes are the most studied species, and their CSF concentrations can be 
measured by gas chromatography/negative ion chemical ionization MS. CSF F2-iso- 
prostanes were found significantly increased in patients with probable AD, compared 
with controls (40;127;128), and compared to FTLD patients (40). Levels were highly 
correlated with disease severity (127; 128). Furthermore, in AD patients and patients 
with non-AD dementias the combined analysis of CSF F2-isoprostane levels, A042 
and t-tau levels resulted in sensitivity of 84% and specificity of 89% (129). Others 
performed a discriminant analysis based on CSF levels of t-tau, A042, and F2-isopros- 
tane and were able to classify 88.5% of patients in a manner that corresponded to 
their clinical or autopsy diagnosis (40). F2-isoprostane levels were also increased in 
CSF o f subjects with MCI, compared to cognitively normal elderly subjects (130). This 
implies that brain oxidative damage starts early in the course of AD, and that F2-iso- 
prostanes can be used as CSF markers before the onset of symptomatic dementia. 
Additional studies, including confirmation by independent research groups, are 
warranted, however, to establish F2-isoprostane analysis as a biomarker for AD.
Cytokines
In AD brains, the pathological lesions, in particular senile plaques, are associated 
with a localized neuro-inflammatory reaction, characterized by activated microglia 
and astrocytes, with increased expression of inflammatory proteins such as cyto­
kines (131). Several cytokines can be detected in CSF, but the results of CSF cytokine 
measurements in dementia patients are still controversial (reviewed by Teunissen 
et al.) (123). In AD patients IL-6 was found increased, decreased, or not significantly
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different from controls in different studies (123;132). CSF concentrations of IL-6 
were also significantly elevated inVaD patients (132; 133). Differentiation of AD and 
VaD by measuring CSF IL-6 levels was possible in one study (133), that could not be 
confirmed by others (132). The same applies for IL-113 and TNF-alpha. Some studies 
found increased CSF levels in AD patients while others did not (123; 132). CSF levels 
of TNF-alpha are also increased in VaD patients (132). In the CSF of FTLD patients 
IL-15 was elevated, and IL-12 levels were reduced (134;135), but the same phenom­
enon was found in AD patients (134; 135).
Thus, although CSF levels o f cytokines in dementia patients appear different 
from controls, their quantifications can not yet be used as biomarkers to differen­
tiate between different dementia disorders. In the future, however, CSF cytokines 
maintain the potential to provide assistance in monitoring treatm ent effects of 
neuroprotective drugs, especially anti-inflammatory drugs.
Neurofilam ents
Neurofilament proteins (NFs) are the major constituents of the neuronal cyto- 
skeleton. They are predominantly localized in large neurons and myelinated axons, 
and play an im portant role in neuronal structure and function. NFs consist of three 
polypeptides with different molecular weights, known as the light (NFL), medium  
(NFM) and heavy (NFH) subunits, respectively (136). Since NFs are released from  
damaged neurons, increased levels of NF protein in CSF may reflect the degree of 
neuronal degeneration in neurological disease.
Since 1996, the analyses of NF proteins in CSF o f patients with different neu- 
rodegenerative disorders, including dementia, challenged various researchers. NFL 
levels in CSF were found to be increased in AD and FTLD, compared to control sub­
jects (137-143). More specifically, CSF NFL levels were elevated in relatively young 
patients with FTLD compared to patients with early-onset AD (141; 143). When com­
bining CSF levels of NFL with p-tauisi and A042, differentiating between FTLD and 
early-onset AD was possible with a sensitivity o f 86%, and specificity of 100% (143).
In contrast to studies on NFL, less is known about the CSF levels o f the other 
two NF subunits in neurodegenerative dementias. Higher CSF levels of phosphory- 
lated NFH/M were found in AD patients compared to VaD patients and controls (137).
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CSF levels o f NFH were increased in patients with AD, VaD, FTLD, and DLB, compared 
to control subjects (143;144). However, discriminating between different dem en­
tia disorders using CSF NFH levels was only possible in DLB versus early-onset AD 
(143).
Although increased CSF levels of NFL and NFH were found in different dementia 
disorders, their analysis showed no superior, and only limited additional, diagnostic 
value compared to the frequently used CSF biomarkers A042, t-tau and p-tauisi (143).
A(3 oligomers
Results from the above-mentioned studies using the SELDI-TOF technology suggest 
the occurrence of A(3 aggregates, particularly dimers, trimers and possibly larger spe­
cies, in CSF o f AD patients. However, the quantification and definite identification 
of such Ap oligomers cannot be achieved by SELDI-TOF, and more specific assays 
are needed for this goal. Already back in 1998, a study was published in which the 
presence at increased concentrations o f A(3 oligomers in CSF was demonstrated by 
seeded polymerization of labeled A(3 onto A(3 oligomeric seeds, visualized by fluo­
rescence correlation spectroscopy (145). More recently, identification of A(3 oligom­
ers in CSF was achieved by a combination of protein immunodetection and DNA 
amplification techniques in the so-called bio-barcode assay (118). A(3 oligomer con­
centrations were increased in AD compared to controls. Advanced A(3 oligomeriza­
tion may lead to an underestimation of A(3 levels, since the commonly used assays 
preferentially detect A(3 monomers (146). Recently, A(3 oligomers were detected 
in CSF by using flow cytometry and fluorescence resonance energy transfer (147). 
Although such oligomers appear to be promising new biomarkers for AD, more vali­
dation studies with large clinically well-defined subgroups of dementia syndromes 
are needed to establish their potential use as a biomarker. Furthermore, more exten­
sive analysis and characterization of the type of A(3 aggregates that are detected by 
the respective assays are needed to assess the robustness o f such assays.
Enzymes
Various enzymes in CSF have been studied as potential biomarkers for AD, but only 
few are promising. The beta-site APP cleaving enzyme 1 (BACE-1) is responsible 
for the first proteolytic event in the cleavage of APP leading to amyloid formation.
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Inhibition of BACE-1 is thought to be a therapeutic approach to AD. CSF BACE-1 
activity was found elevated in AD patients in comparison with a group o f patients 
with other dementias (148). Thus, detection of BACE-1 in CSF may have diagnos­
tic applications, and may also be useful for monitoring the effects of drugs. Further 
research is needed.
Another potentially useful enzyme is the angiotensin converting enzyme 
(ACE). There is increasing evidence that ACE plays a role in the development of AD. It 
has been suggested that decreased ACE activity may influence the susceptibility to 
AD by a mechanism involving Ap metabolism (149). However, no difference in CSF 
ACE levels was found between AD, DLB and controls (150). Others found elevated 
CSF ACE activity in AD-converted MCI patients and mild to moderate AD patients 
as compared to controls (151). A brain-penetrating ACE-inhibitor was able to signifi­
cantly inhibit CSF ACE activity in AD patients (151). Thus, a role for ACE as a possible 
marker for disease and drug effects remains a possibility.
Plasma biomarkers for AD
Since blood is easier accessible than cerebrospinal fluid, the search is on for useful 
plasma biomarkers, especially Ap4oandAp42. Although there was no relation between 
plasma AP40 and AP42 levels and those in CSF (152), or between plasma Ap levels 
and brain Ap levels (153), some groups reported increased plasma AP42 levels in AD 
patients or MCI patients that converted to AD (154-156). Plasma AP40 levels were 
not increased in these patients (154; 157). Similar to biomarkers in CSF, an increased 
ratio of plasma AP42 and AP40 levels correlated with a decrease in dementia risk (158), 
and vice versa (159). In most studies, plasma AP42 levels were positively correlated 
with age (154;157), but not with cognitive impairment or duration of the disease 
(152; 157). Thus, when interpreting the results o f plasma Ap levels, the effect of age 
should be taken into account. Also, the consequence of concomitant medication 
should be considered. Increased levels of plasma AP42 were found in non-demented  
subjects who used insulin and biguanides, decreased levels in users of gingko biloba 
and statin users, and a nonsignificant trend to reduced levels was found in users of 
nonsteroidal anti-inflammatory drugs (NSAIDs) (160). Although another study could
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not confirm the altered plasma A042 levels in statin and NSAID users (157), these 
findings will complicate the interpretation of the results.
In conclusion, measurement of plasma A042 levels or the plasma AfWAf^o 
ratio is currently not useful for the diagnosis of AD, but it may be interpreted as a 
biological risk factor. Changes related to specific medication should be taken into 
account.
What is the future of biomarkers for AD?
Still the most successful neurochemical biomarkers for AD are the analysis in CSF 
of A042, t-tau, and p-tauisi. However, CSF analysis of t-tau, p-tau and A042 also has 
some limitations. Although the test characteristics are excellent to differentiate AD 
from controls, the real challenge is in the differentiation of AD from other demen­
tia disorders, that commonly include prion disease (e.g. CJD), VaD, tauopathies (e.g. 
FTLD, progressive supranuclear palsy) and a-synucleinopathies (DLB, Parkinson's dis­
ease). CJD can be identified by CSF analysis of, particularly, 14-3-3 and t-tau proteins 
with very high sensitivity and specificity. However, only a very small proportion of 
dementia patients suffers from CJD (incidence 1-1.5:1,000,000 people). Furthermore, 
we demonstrated that AD can be very well differentiated from VaD by calculating 
the AfWp-tau ratio, which accurately separates both disorders (sensitivity, specific­
ity and negative/positive predictive values> 85%) (51). However, the differentiation 
of AD from other dementia syndromes remains a challenge and is not optimal by 
using these CSF biomarkers. Basically this is caused by low A042 levels in DLB and 
highly variable t-tau and p-tau levels in FTLD. Therefore, the application of CSF test­
ing seems to be particularly restricted to the identification of AD patients amongst a 
population of dementia patients.
Essentially, almost all studies aimed at the estimation of the diagnostic accu­
racy of CSF analysis in dementia syndromes have been carried out in specific and 
selected patient cohorts as part of retrospective case-control studies, in expert 
referral clinics, and usually not based on predetermined cut-off values ("phase I and 
lla,b") (161). Phase III studies, in which one should use the test with predetermined 
cut-off values to discriminate between cases and non-cases, have been attempted,
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but mostly failed because of insufficient blinding of the clinicians for the CSF mea­
surements in the process of defining a diagnosis and in the omission of strictly pre­
defined cut-off values. Extension of the studies referred here with a "phase lll"clinical 
effectiveness study, in which the additional value of CSF analysis will be investigated 
in a cohort of patients visiting memory clinics, will be an essential step forward in 
the evaluation of the validity of CSF testing in the diagnostic pathway for AD as it 
appears in daily practice.
A recent study described how new diagnostic tests can be categorized and 
tested against existing diagnostic pathways (162). Three different types of new diag­
nostic tests can be defined: 1) Replacement tests. The introduction of a new test is 
superior to existing diagnostic test and entirely replaces the old ones; 2) Triage tests. 
Triage tests may be less accurate than existing ones, but may be performed prior to 
the existing tests as a first line of rapid screening; 3) Add-on tests. This type of tests 
does not replace existing tests and is performed after these existing tests in a spe­
cific subgroup of patients. Typically, CSF analysis of t-tau, p-tau and A042 should be 
regarded as "add-on" tests in the diagnostic pathways, since in cases of an unequivocal 
clinical diagnosis of AD or non-AD, additional diagnostic investigations including 
CSF analysis, are not indicated. We have recently started a diagnostic phase III study 
in a population of patients visiting a memory clinic for evaluation of their dementia 
syndrome, in which the diagnostic value of CSF analysis of A042, t-tau, and p-tauisi 
will be evaluated in an add-on design.
In conclusion, CSF analysis of t-tau, p-tau and A042 is still the standard in the 
neurochemical diagnosis of AD. Novel biomarkers for AD are extensively searched 
for by several research groups. Novel technologies, including MS analysis, may lead 
to the discovery of new biomarkers. Probably the most promising type of new bio­
markers are still to be found in CSF. However, if new techniques that allow for the 
sensitive detection of very low levels of brain-specific proteins are being developed, 
it is most feasible that biomarker analysis in CSF will be replaced by the more easily 
accessible blood. The presence of assembled forms of A(3 (dimers, trimers, oligomers) 
may serve as potential biomarkers for AD. In addition, N- or C-terminally truncated 
Ap peptides may also add to the diagnostic specificity of CSF analysis for AD. Specific 
and robust tests to detect this variety of A(3 (-derived) peptides and aggregates need 
to be developed, however. Furthermore, the analysis of isoprostanes, and possibly
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other specific metabolites related to the oxidative process in AD, may serve as a bio­
marker. Confirming studies by other groups should be performed, however. For all 
the newly described potential biomarkers extensive phase I and II studies will have 
to be performed, however, before they can be evaluated in clinical practice.
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Summary
Alzheimer's disease and anti-inflammatory drugs
The objective of this part of the thesis was to explore the role of inflammation in the 
pathogenesis of Alzheimer's disease (AD), and to investigate whether anti-inflam- 
matory drugs, especially nonsteroidal anti-inflammatory drugs (NSAIDs), are able to 
retard the progression of AD.
In Chapter 2.1 we reviewed the different lines of research regarding AD and 
inflammation. In 1982, the first indications that inflammation plays a role in AD were 
found in post-mortem brains of AD patients. Additional neuropathological research 
revealed that various inflammatory mediators are found within and surrounding 
amyloid plaques in AD brains. Epidemiological studies consistently demonstrated 
that the use of NSAIDs prior to incipient disease is associated with a reduced risk for 
the development of AD. Research concerning the mechanism of action of NSAIDs in 
AD revealed that the effect of NSAIDs in AD is probably mediated by activation of the 
peroxisome proliferator-activated receptor-y. In animal model studies it was demon­
strated that the administration of NSAIDs to AD transgenic mice suppressed the for­
mation of amyloid plaques and inflammatory mediators. In cultured cells, a subset 
of NSAIDs was found to lower the amount of amyloid 042 secretion. Together, these 
findings raised the suggestion that NSAIDs will be able not only to postpone AD 
onset (primary prevention) but also to retard AD progression. In 2000, when our ran­
domized controlled trial with the NSAID indomethacin started (see chapter 2.2), only 
one small clinical trial had shown that treatment with NSAIDs significantly delayed 
cognitive decline in AD patients. We concluded that large randomized double-blind 
placebo-controlled trials were needed to demonstrate a definite beneficial effect of 
NSAIDs in AD.
In chapter 2.2 we described the methods and results of a double-blind, ran­
domized, placebo-controlled trial with indomethacin in AD patients. Our objective 
was to assess whether treatment with the NSAID indomethacin slows cognitive 
decline in patients with AD. The study was conducted between May 2000 and 
September 2005 in two hospitals in the Netherlands. Fifty-one patients with mild to 
moderate AD were enrolled into the study. Patients received 100 mg indomethacin 
or placebo daily for 12 months. Additionally, all patients received omeprazole as a
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gastroprotectant. The primary outcome measure was the change from baseline on 
the cognitive subscale of the AD Assessment Scale (ADAS-cog) over the one year 
treatment period. Secondary outcome measures included the Mini-Mental State 
Examination, the Clinician's Interview Based Impression of Change with caregiver 
input, the noncognitive subscale of the ADAS, the Neuropsychiatric Inventory, and 
the Interview for Deterioration in Daily life in Dementia. Unfortunately, consider­
able recruitment problems of participants were encountered, leading to an under­
powered study. In the placebo group, 19 out of 25 patients completed the study, and 
in the indomethacin group 19 out of 26. The deterioration on the ADAS-cog was less 
in the indomethacin group (7.8 ± 7.6), than in the placebo group (9.3 ± 10.0). This dif­
ference (1.5 points; Cl -4.5 - 7.5) was not statistically significant; neither were any of 
the secondary outcome measures. Indomethacin, in combination with omeprazole, 
was reasonably well tolerated in the elderly trial patients without serious gastroin­
testinal tract events. We concluded that the results of our study were inconclusive 
with respect to the hypothesis that indomethacin slows the progression of AD.
In Chapter 2.3 we investigated the external validity of the results of our pre­
viously conducted randomized controlled trial (RCT), and we evaluated the gen- 
eralizability of the results of other drug-trials in AD patients. All AD patients that 
participated in our RCT with indomethacin (RCT group, n = 51), were compared with 
all remaining AD patients seen at our memory clinic for diagnosis and treatment 
during the four-year recruitment period of the trial (control group, n = 128). Charac­
teristics of these patients, such as medication use, comorbidity, results of physical 
and neurological examination, were collected. The Cumulative Illness Rating Scale 
for Geriatrics was used to assess the presence and severity of comorbidity. Further­
more, 72 RCTs with AD patients in which various drugs were tested, were selected 
from the literature for further comparisons. We found that the age of the patients 
in the RCT group was significantly lower (72.4 ± 8.0 years) than in the control group 
(76.1 ± 6.5 years; p<0.01). Furthermore, patients in the RCT group had fewer dis­
abilities and comorbid conditions, and were taking less medication, than those in 
the control group. In 62 out of 72 evaluated other RCTs mean age of participating 
patients was < 76 years. In only 11 RCT articles some information was available on 
medication use or comorbidity of participants. Thus, we concluded that the external 
validity of the results of our RCT with indomethacin, and of many other RCTs with
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AD patients, is limited. Also, care should be taken to extrapolate conclusions from 
clinical trials to a general population of AD patients.
Cerebrospinal fluid diagnosis in Alzheimer's disease
Differentiating AD from other dementia disorders, such as vascular dementia (VaD), 
frontotemporal lobar degeneration (FTLD), and dementia with Lewy bodies (DLB) 
is becoming increasingly important. An accurate and early diagnosis is essential for 
appropriate support and treatment of dementia patients, since symptomatic drugs 
are already available for AD patients, and neuroprotective drugs are being devel­
oped. However, the clinical diagnostic criteria currently used for the differentiation 
between AD and other dementias have disappointing sensitivity and specificity.
The objective of this part of the thesis was to investigate whether the analysis 
of biomarkers, especially in cerebrospinal fluid (CSF), could be helpful in discriminat­
ing AD from other dementias.
In chapter 3.1 we focused on the differentiation of AD from VaD. The objec­
tive of this study was to investigate whether CSF levels of total tau protein (t-tau), 
amyloid 042 protein (A042) and tau phosphorylated at threonine 181 (p-tauisi) are 
useful biomarkers to distinguish AD patients from VaD patients. We measured CSF 
levels of p-tauisi, A042, and t-tau in patients with mild to moderate AD (n = 61) and 
VaD (n = 25), and 30 control subjects (NC). Optimal differentiation between AD and 
VaD was achieved by using the ratio of the CSF levels of A042 and p-tauisi (Q A042/ 
p-tau) with sensitivity, specificity, positive and negative predictive values all > 85%. 
We concluded that our results support further efforts to prospectively validate the 
use of Q A042/p-tau as a biomarker to differentiate between AD and VaD.
In chapter 3.2 we investigated the diagnostic value of CSF neurofilament (NF) 
protein analysis in relatively young dementia patients to differentiate between FTLD 
and early-onset AD (EAD; onset < 65 years of age), and in elderly dementia patients 
between DLB and late-onset AD (LAD; onset > 65 years of age). NF proteins are 
major cytoskeletal constituents of neurons. Increased CSF NF levels may reflect neu­
ronal damage during degeneration. In CSF of 28 FTLD, 37 EAD, 18 DLB, and 33 LAD 
patients, and 26 control subjects, we analysed NF light chain (NFL), phosphorylated 
NF heavy chain (pNFH), A042, t-tau, and p-tauisi. CSF NFL levels were higher in FTLD 
patients compared to EAD patients (p < 0.001), and diagnostic accuracy of p-tauisi
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and A042 analysis improved with the addition of NFL analysis (sensitivity 86%, speci­
ficity 100%). CSF pNFH levels were elevated in DLB, LAD, and FTLD compared to 
controls (p < 0.05), but no significant differences were found between the various 
dementia groups. We concluded that in the diagnostic workup of relatively young 
dementia patients, CSF NFL levels may play a role in the discrimination between 
FTLD and EAD, especially in combination with A042 and p-tauisi analysis.
Chapter 3.3 offers a comprehensive review of the literature on neurochemical 
biomarkers for AD. We summarized the current state-of-the-art of these biomarkers. 
Predominantly, these biomarkers are cerebrospinal fluid biomarkers directly related 
to the pathofysiology of this disorder (such as amyloid (3 protein, tau protein). We 
particularly paid attention to the innovations in this area that have been made in 
technological aspects during the past 5 years (e.g. multiplex analysis of biomarkers, 
proteomics), to the discovery of novel, potential biomarkers (e.g amyloid (3 oligo­
mers, isoprostanes), and to the extension of this research towards identification of 
biomarkers in plasma.
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General discussion
Alzheimer's disease and anti-inflammatory drugs
AD is a complex and devastating neurodegenerativo disorder for which the currently 
available drugs offer only a modest symptomatic effect. Animal studies, in vitro data, 
and epidemiologic evidence strongly supports the hypothesis that NSAIDs have dis- 
ease-modifying properties (chapter 2.1). However, our randomized clinical trial with 
the NSAID indomethacin failed to show an effect on the progression of AD (chapter 
2.2). Although our trial was hampered by extensive exclusion criteria which resulted 
in a underpowered study, low external validity (chapter 2.3), and inconclusive results, 
the disappointing results of other trials with various NSAIDs (diclofenac/misoprostol, 
ibuprofen, naproxen, rofecoxib, nimesulide, and celecoxib) sheds serious doubts on 
the hypothesis.(1-6) Nevertheless, there is still a vast belief among many researchers 
that NSAIDs can prevent or slow the progression of AD.
The failure of clinical trials with NSAIDs in AD patients has led to many specu­
lations why there was no response. Several possible reasons have been suggested. 
First, the dosage of the drug used, or the level that the drug of interest reaches in 
the central nervous system could be too low. Especially naproxen was given at a low- 
dose to prevent side-effects, which might be responsible for the failure of this trial.
(2) A second reason could be the timing of the intervention. It may be questioned 
whether anti-inflammatory treatment will be efficacious in treating symptomatic 
AD. Even when given in an earlier stage of the disease, there seems not to be an 
effect; In a randomized controlled study in patients with mild cognitive impairment 
(MCI), rofecoxib could not delay a diagnosis of AD in patients with MCI.(7) Possibly 
NSAIDs only have primary preventive effects, and are no longer effective in patients 
with developing or established disease. However, the results of the Alzheimer's Dis­
ease Anti-inflammatory Prevention Trial (ADAPT), in which men and women aged 
70 years and older with a family history of AD were randomly assigned to receive 
naproxen, celecoxib or placebo, did not support a preventive effect either.(8) These 
results appear to be inconsistent with the epidemiological findings that originally 
provided the rationale for this trial (chapter 2.1). In that case, the final option is that 
NSAIDs might exert protective effects only if given numerous years before the time 
when symptoms would otherwise develop. This agrees with the results of the Rotter­
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dam and Cache County observational studies, which showed protective effects with 
more distant, but not recent, use of NSAIDs.(9;10) A recent epidemiological study in 
an older cohort (median age 74.8 years) found an increased incidence of dementia 
and AD in heavy NSAID users,(11) which might also be an argument for the use of 
NSAIDs a long time before AD symptoms develop.
A different explanation for the negative results of the ADAPT study and other 
trials with NSAIDs concerns the pharmacological and pharmacokinetic properties of 
the drugs being used. Initially, investigators were mainly interested in the cyclooxy- 
genase (COX)-inhibiting properties of NSAIDs (chapter 2.1). Selective COX-2 inhibi­
tors with a more favorable side-effects profile were being developed. Clinical trials 
followed with celecoxib and rofecoxib in AD patients, patients with MCI, and elderly 
patients with a family history of AD, but none showed a significant effect.(2;4;6;7;12) 
As COX-inhibition by NSAIDs appeared not to play an important role, attention 
shifted towards an alternative mechanism of action of NSAIDs: the activation of 
the peroxisome proliferator-activated receptor-gamma (PPAR-y), a nuclear receptor 
(chapter 2.1). Most classical NSAIDs, such as indomethacin, naproxen, and ibuprofen 
are PPAR-y agonists, with the exception of diclofenac, which is only a partial agonist. 
(13; 14) However, all clinical trials using NSAIDs that activate PPAR-y failed to show an 
effect (chapter 2.2).(2;3;8;12)
A subset of NSAIDs, such as ibuprofen or flurbiprofen, have Ap42-lowering prop­
erties by modulating the activity of gamma-secretase (chapter 2.1). Although ibu­
profen failed to show an effect in AD patients, evidence was found of a dose-related 
effect in patients with mild AD in a phase II trial with tarenflurbil (R-flurbiprofen). 
(3; 15) However, the results of the largest and longest phase III trial in mild AD patients 
with tarenflurbil were very disappointing; Tarenflurbil failed to distinguish itself from 
placebo in its primary endpoints of slowing decline in AD.(16) A simple explanation 
of this failure might be that the gamma-secretase is not the right target for therapy or 
that, in general, blocking A042 does not produce clinical benefits in AD.
Conclusion and future perspectives
Since many clinical trials testing various NSAIDs at different stages of AD (pre-symp- 
tomatic, MCI, mild and moderate AD) failed to show an effect, there is not much 
hope left that a NSAID can either treat or prevent AD. Therefore, we do not recom­
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mend further treatment trials with NSAIDs in AD patients. Nevertheless, a primary 
prevention trial with ibuprofen in middle aged individuals (approximately between 
the ages of 40 and 60 years) is still warranted to further investigate the effect of long­
term NSAID use on risk of AD.
Cerebrospinal fluid diagnosis in Alzheimer's disease
Despite extensive research on this topic, the most successful neurochemical bio­
markers for AD in CSF still remain A042, t-tau, and p-tauisi (chapter 3.3). Test charac­
teristics are excellent to differentiate AD from controls using these CSF biomarkers. 
Moreover, there is increasing evidence that levels of these biomarkers correlate with 
clinical and neuropathological features in AD patients. In individuals with very mild 
AD, lower CSF A042 levels, high t-tau or ptauisi levels, or high ratio of CSF levels of 
t-tau and A042 quantitatively predict more rapid progression of cognitive deficits 
and dementia.(17) Pathological CSF levels of A042, t-tau, and ptauisi are strongly 
associated with future development of AD in patients with MCI.(18-20) Also, CSF 
A042 levels correlate inversely with total Ap load in the brain, and CSF t-tau levels 
correlate with the presence of neocortical neurofibrillary tangles.(21) Furthermore, 
increased CSF p-tau levels are independently associated with faster subsequent dis­
ease progression, as reflected by higher hippocampal atrophy rates.(22) A subgroup 
of patients with extremely high CSF t-tau and ptauisi levels shows a distinct cogni­
tive profile with more severe impairment of memory, mental speed, and executive 
functions, which cannot be explained by disease severity.(23) Altogether, CSF A042, 
t-tau, and p-tauisi have proven their value in AD in many ways.
When using these biomarkers in clinical practice, however, standardized (pre) 
analytical procedures should be followed for correct and reliable analysis of A042, 
t-tau, and p-tauisi levels. CSF withdrawal should be performed in polypropylene 
tubes, and at a standardized time point of the day, because of diurnal fluctuations of 
Ap concentrations.(24;25) CSF samples must be centrifuged, aliquoted and stored at 
-80°C as soon as possible after withdrawal.(26) Furthermore, the same assay should 
always be used to decrease intracenter, and intercenter variation.(27)
Differentiating AD from other dementia disorders, including DLB, FTLD and 
VaD, using CSF AP42, t-tau, and p-tauisi is more difficult, although the ratio of CSF
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levels of A042 and p-tauisi (Q AfWp-tau) can be helpful for the differentiation 
between AD and VaD with sensitivity, specificity, positive and negative predictive 
values all > 85% (chapter 3.1). In some cases, the t-tau/p-tauisi ratio in CSF may con­
tribute to the clinical distinction between DLB and AD, but the value of the markers 
is still limited.(28) Thus, additional biomarkers are needed. In the diagnostic workup 
of relatively young dementia patients, we found that CSF NFL levels in combination 
with A042 and p-tauisi analysis are helpful in the discrimination between FTLD and 
EAD (chapter 3.2). However, since our review was published in 2007 (chapter 3.3), 
no promising novel biomarkers have been introduced. Now, attention has shifted 
towards combining neurochemical biomarkers in CSF, structural neuroimaging with 
MRI, and molecular neuroimaging with PET in order to optimize the diagnosis of AD, 
and other dementia syndromes. Already, revised research criteria for AD have been 
proposed that implements these biomarkers.(29)
Conclusion and future perspectives
The value of the CSF biomarkers A042, t-tau, and p-tauisi in AD is well established. 
However, the differentiation between AD, DLB, FTLD and VaD using CSF biomarkers 
still needs to be improved. Further research should focus on finding specific CSF bio­
markers in FTLD, VaD, and DLB. Preferably, these biomarkers should correlate with 
neuropathological findings in these patients. Novel technologies, including mass 
spectrometry analysis, may lead to the discovery of new biomarkers. Probably the 
most promising type of new biomarkers are still to be found in CSF.
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De ziekte van Alzheimer en anti-infammatoire geneesmiddelen
Het doel van het eerste deel van het proefschrift was het bestuderen van de aspec­
ten en de rol van ontstekingsreacties in de hersenen bij mensen met de ziekte van 
Alzheimer, en vervolgens te onderzoeken of ontstekingsremmende geneesmidde­
len, met name niet-steroide anti-inflammatoire middelen (NSAID's), de progressie 
van deze ziekte kunnen vertragen.
In hoofdstuk 2.1 hebben we de verschillende onderzoekslijnen betreffende 
de ziekte van Alzheimer en ontsteking samengevat. In 1982 werden de eerste aan­
wijzingen gevonden dat ontstekingsprocessen in de hersenen een rol spelen bij de 
ziekte van Alzheimer. Daaropvolgend neuropathologisch onderzoek toonde aan dat 
diverse ontstekingsmediatoren aanwezig zijn in en rondom amyloïde plaques in her­
senen van patiënten met de ziekte van Alzheimer. Diverse epidemiologische studies 
toonden aan dat het gebruik van NSAID's voorafgaand aan het begin van de ziekte 
geassocieerd is met een verminderd risico op het ontwikkelen van de ziekte van 
Alzheimer. Bij onderzoeknaar het werkingsmechanisme van NSAID's bij de ziekte van 
Alzheimer werd gevonden dat het effect van NSAID's bij deze ziekte waarschijnlijk 
gemedieerd wordt door de activatie van de peroxisoom-proliferator-geactiveerde 
receptor-y. Toepassing van NSAID's in een muizenmodel van de ziekte van Alzhei­
mer bleek de vorming van amyloïde plaques en ontstekingsmediatoren te remmen. 
In gekweekte cellen bleek tevens dat diverse NSAID's de hoeveelheid amyloïd 042 
afgifte kunnen remmen. Bovenstaande bevindingen deden vermoeden dat NSAID's 
in staat zijn om niet alleen het ontstaan van de ziekte van Alzheimer uit te stellen 
(primaire preventie), maar ook de progressie van deze ziekte te vertragen. Tijdens 
de start van onze dubbelblinde gerandomiseerde placebogecontroleerde klinische 
trial met de NSAID indometacine in het jaar 2000 (zie hoofdstuk 2.2) was nog maar 
bij 1 kleine klinische studie bij alzheimerpatiënten een significante afname van de 
cognitieve achteruitgang gevonden bij gebruik van een NSAID. Wij concludeerden 
dat grote gerandomiseerde dubbelblinde placebogecontroleerde klinische trials 
nodig waren om een zeker positief effect van het gebruik van NSAID's bij de ziekte 
van Alzheimer aan te tonen.
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In hoofdstuk 2.2 beschrijven we de methoden en resultaten van zo'n dubbel­
blinde gerandomiseerde placebogecontroleerde klinische trial met indometacine in 
alzheimerpatiënten. Het doel van de studie was te onderzoeken of behandeling met 
de NSAID indometacine de cognitieve achteruitgang zou vertragen bij patiënten 
met de ziekte van Alzheimer. Deze studie werd uitgevoerd in twee ziekenhuizen in 
Nederland in de periode van mei 2000 tot september 2005. Eenenvijftig patiënten 
met lichte tot matig ernstige ziekte van Alzheimer werden geïncludeerd in de studie. 
Patiënten werden behandeld met indometacine (100 mg per dag) of placebo. Daar­
naast kregen alle patiënten de maagbeschermer omeprazol voorgeschreven. De 
primaire uitkomstmaat voor de studie was de verandering na 1 jaar ten opzichte 
van de uitgangssituatie, gemeten met de cognitieve deelschaal van de"Alzheimer's 
Disease Assessment Scale" (ADAS-cog). De "Mini-Mental State Examination", de 
"Clinician's Interview Based Impression of Change with caregiver input" de niet- 
cognitieve deelschaal van de ADAS, de"Neuropsychiatric lnventory",en de"lnterview 
for Deterioration in Daily life in Dementia" werden gebruikt als secundaire uitkomst­
maat. Helaas werden aanzienlijke problemen ondervonden met het includeren van 
patiënten, waardoor de studie onvoldoende statistische power had. In de placebo 
groep hebben 19 van de 25 patiënten de studie afgerond en in de indometacine 
groep 19 van de 26 patiënten. De achteruitgang gemeten met de ADAS-cog was 
minder in de indometacine groep (7.8 ± 7.6) dan in de placebo groep (9.3 ± 10.0). Dit 
verschil (1.5 punten; Cl -4.5 - 7.5) was echter niet statistisch significant; evenmin als 
de secundaire uitkomstmaten. Indometacine, in combinatie met omeprazol, werd 
vrij goed verdragen in de oudere deelnemende patiënten, zonder ernstige gastro- 
intestinale bijwerkingen. Wij moesten concluderen dat de resultaten van onze studie 
geen uitspraak toelieten aangaande de hypothese dat indometacine de progressie 
van de ziekte van Alzheimer zou vertragen.
In hoofdstuk 2.3 onderzochten we de externe validiteit van de resultaten van 
onze tevoren verrichtte dubbelblinde gerandomiseerde placebogecontroleerde kli­
nische trial en evalueerden wedegeneraliseerbaarheid van de resultaten van andere 
klinische trials bij alzheimerpatiënten. Alle alzheimerpatiënten die deelnamen 
aan onze klinische trial met indometacine (trial groep, n = 51) werden vergeleken 
met alle overgebleven alzheimerpatiënten die op de geheugenpolikliniek waren
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gezien gedurende de vier jaar durende inclusie periode van de trial (controle groep, 
n = 128). De karakteristieken van deze patiënten, zoals medicatie gebruik, comor- 
biditeit, resultaten van algemeen lichamelijk en neurologisch onderzoek, werden 
verzameld. De"Cumulative lllness Rating ScaleforGeriatrics"(CIRS-G) werd gebruikt 
om de aanwezigheid en de ernst van de comobiditeit te bepalen. Ter vergelijking 
werden verder nog 72 gerandomiseerde placebogecontroleerde klinische trials uit 
de literatuur geselecteerd waarin verschillende geneesmiddelen zijn getest bij alz- 
heimerpatiënten. De leeftijd van de patiënten in de trial groep (72.4 ± 8.0 jaar) bleek 
significant lager te zijn dan in de controle groep (76.1 ± 6.5 jaar; p<0.01). Bovendien 
bleken patiënten in de trial groep minder handicaps en comorbide aandoeningen 
te hebben en minder geneesmiddelen te gebruiken dan de patiënten in de controle 
groep. In 62 van de 72 geëvalueerde overige klinische trials was de gemiddelde leef­
tijd van de deelnemende patiënten < 76 jaar. Uiteindelijk hebben wij geconcludeerd 
dat de externe validiteit van de resultaten van onze klinische trial met indometacine, 
evenals van vele andere klinische trials, beperkt is. Bovendien is voorzichtigheid 
geboden met het extrapoleren van conclusies van klinische trials naar de doorsnee 
populatie alzheimerpatiënten.
Liquor cerebrospinalis diagnose bij de ziekte van Alzheimer
Het onderscheiden van de ziekte van Alzheimer van andere dementie syndromen, 
zoals vasculaire dementie, frontotemporale lobaire degeneratie en dementie met 
Lewy lichaampjes, wordt steeds belangrijker. Een accurate en vroege diagnose is 
essentieel voor de juiste ondersteuning en behandeling van dementie patiënten, 
aangezien er al symptomatische geneesmiddelen beschikbaar zijn voor alzheimer­
patiënten en neuroprotectieve geneesmiddelen in ontwikkeling zijn. Echter, de 
klinische criteria die momenteel gebruikt worden om de ziekte van Alzheimer te 
differentiëren van andere dementie syndromen hebben een teleurstellende sensi­
tiviteit en specificiteit.
Het doel van dit deel van het proefschrift was te onderzoeken of de analyse 
van biomarkers, met name in de liquor cerebrospinalis (hersenvocht), behulpzaam 
zou kunnen zijn bij het onderscheiden van de ziekte van Alzheimer van andere 
dementie syndromen.
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In hoofdstuk 3.1 hebben we ons gericht op de differentiatie tussen de ziekte 
van Alzheimer en vasculaire dementie. Het doel van deze studiewas te onderzoeken 
of de concentraties van het totale tau eiwit (t-tau), het amyloïd ß42 eiwit (Aß42) en 
gefosforyleerd tau op threonine 181 (p-tauisi) waardevolle biomarkers zijn waarmee 
alzheimerpatiënten van patiënten met vasculaire dementie onderscheiden kunnen 
worden. We maten de liquor concentraties van p-tauisi, Aß42, en t-tau bij patiënten 
met milde tot matig ernstige ziekte van Alzheimer (n = 61), bij patiënten met vas­
culaire dementie (n = 25) en bij controle personen (n = 30). De meest optimale dif­
ferentiatie tussen de ziekte van Alzheimer en vasculaire dementie werd bereikt met 
behulp van de ratio van de liquor concentraties van Aß42 en p-tauisi (Q Aß42/p-tau), 
met een sensitiviteit, specificiteit, positief en negatief voorspellende waarde van > 
85%. Wij concludeerden dat onze resultaten verdere pogingen ondersteunen om 
prospectief het gebruik van Q Aß42/p-tau, als biomarker om te differentiëren tussen 
de ziekte van Alzheimer en vasculaire dementie, te valideren.
In hoofdstuk 3.2 hebben we de diagnostische waarde onderzocht van neu- 
rofilament (NF) eiwit analyse in de liquor van relatief jonge dementie patiënten 
om te kunnen differentiëren tussen frontotemporale lobaire degeneratie (FTLD) en 
de ziekte van Alzheimer die op jonge leeftijd is ontstaan (< 65 jaar; EAD). Onder 
oudere dementie patiënten is gekeken naar de differentiatie tussen dementie met 
Lewy lichaampjes (DLB) en de ziekte van Alzheimer die op latere leeftijd is ontstaan 
(> 65 jaar; LAD). NF eiwitten zijn belangrijke cytoskelet bestanddelen van neuronen. 
Verhoogde NF concentraties in de liquor duiden op neuronale schade tijdens dege­
neratie. In de liquor van 28 FTLD, 37 EAD, 18 DLB, en 33 LAD patiënten, alsmede 
26 controle personen, analyseerden we lichte keten NF (NFL), gefosforyleerd zware 
keten NF (pNFH), Aß42, t-tau en p-tauisi. NFL concentraties in de liquor bleken hoger 
in FTLD patiënten vergeleken met EAD patiënten (p < 0.001), en de diagnostische 
accuratesse van de p-tauisi en Aß42 analyse verbeterde met de toevoeging van de 
NFL analyse (sensitiviteit 86%, specificiteit 100%). pNFH concentraties in de liquor 
waren verhoogd in DLB, LAD en FTLD vergeleken met controles (p < 0.05), maar er 
werden geen significante verschillen gevonden tussen de verschillende dementie 
groepen onderling. Wij concludeerden dat in de diagnostische workup van relatief 
jonge dementie patiënten de analyse van NF concentraties in de liquor een rol kan
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spelen in het onderscheid tussen FTLD en EAD, met name in combinatie met A042 
en p-tauisi analyse.
Hoofdstuk 3.3 betreft een uitgebreid overzicht van de literatuur op het 
gebied van neurochemische biomarkers voor de ziekte van Alzheimer. De laatste 
ontwikkelingen op het gebied van deze biomarkers zijn samengevat. Hoofdzakelijk 
betreft het biomarkers in de liquor cerebrospinalis, die direct gerelateerd zijn aan 
de pathofysiologie van deze ziekte (zoals amyloïd (3 en tau eiwit). We hebben in het 
bijzonder aandacht besteed aan de technische innovaties van de afgelopen jaren 
op dit gebied (zoals multiplex analyse van biomarkers, proteomics), aan de ontdek­
king van nieuwe potentiele biomarkers (zoals amyloïd (3 oligomeren, isoprostanen) 
en aan de uitbreiding van onderzoek richting de identificatie van biomarkers in het 
bloed.
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Een proefschrift komt niet tot stand zonder de medewerking, steun, inspiratie en 
aanmoediging van vele anderen. Deze personen zou ik dan ook allen willen bedan­
ken en een aantal daarvan in het bijzonder.
Allereerst wil ik de patiënten met de ziekte van Alzheimer en hun naasten bedanken 
voor de deelname aan mijn onderzoek. Zonder u was dit boekje er niet geweest. 
Door de vaak openhartige gesprekken die we gevoerd hebben, heb ik veel geleerd 
over de impact van deze ziekte op het dagelijks leven. Dit heeft een diepe indruk 
op mij gemaakt. Hoewel mijn aandacht nu verschoven is in de richting de epilepsie, 
zal ik de zoektocht naar een medicijn dat deze ziekte kan genezen altijd op de voet 
blijven volgen. Ik hoop dat dit niet lang meer zal duren.
Vervolgens mijn promotor, prof. dr. H.P.H. Kremer. Beste Berry, bedankt voor het onuit­
puttelijke enthousiasme voor mijn onderzoek en het vertrouwen dat het allemaal 
wel goed zou komen, ook op de momenten dat het onderzoeken/of mijn motivatie 
in een diep dal verkeerde. De snelheid waarin jij de eerste versies van mijn artikelen 
rood deed kleuren was indrukwekkend. Ik heb veel van je geleerd, niet alleen op het 
gebied van wetenschappelijk onderzoek, maar ook tijdens mijn opleiding.
Verdergaat mijn dank uit naar dr. R.W.M.M. Jansen, een van mijn twee copromotores. 
Beste Rene, je nuchtere inbreng tijdens de besprekingen en je invalshoek vanuit de 
klinische geriatrie zijn van essentieel belang geweest voor mijn onderzoek. Het multi­
disciplinaire werken op de geheugenpolikliniek, waarbij de patiënt centraal staat, is 
de inspiratie geweest voor mijn huidige functie.
En dan mijn tweede copromotor, dr. ir. M.M. Verbeek. Beste Marcel, op het moment 
dat duidelijk werd dat het afronden van het klinische deel van mijn onderzoek nog 
lang zou gaan duren, heb je mij de kans gegeven mij te verdiepen in de liquor- 
diagnostiek bij dementie. Je indrukwekkende kennis op dit gebied en je geweldige 
humor hebben er voor gezorgd dat ook dit deel van mijn onderzoek tot een mooi 
einde is gekomen.
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Alle medeauteurs van de artikelen en personen, die op een of andere manier een 
bijdrage aan de artikelen hebben geleverd, wil ik graag bedanken. In het bijzonder 
wil ik bedanken George Borm, voor de statistische ondersteuning, Arenda van Beek, 
voor het opzetten van de database van geheugenpolikliniek patiënten, David Burger, 
voor de farmaceutische ondersteuning en de analisten van het neurochemisch labo­
ratorium voor het analyseren van de liquormonsters.
Tevens wil in de afdeling Neurologie en met name mijn opleider prof. dr. G.W.A.M. 
Padberg bedanken voor de gelegenheid die ik gekregen heb om dit onderzoek te 
doen. De afdeling Geriatrie ben ik zeer erkentelijk voor de gastvrijheid en behulp­
zaamheid.
De (oud-) assistenten neurologie wil ik bedanken voor de gezelligheid en de saam­
horigheid. Ik heb veel goede herinneringen aan mijn tijd op de vijfde verdieping.
Verder ben ik heel erg blij dat mijn oud-carpool genootjes mijn paranimfen willen 
zijn. Lieve Mariëlle, we hebben samen ongeveer 60.000 km afgelegd en tijdens de 
reistijd (die steeds maar langer werd) lief en leed gedeeld. Lieve Anouk (of Noekie, 
zoals mijn oudste dochter je noemde), ook met jou heb ik vele gezellige kilometers 
afgelegd, wat het reizen een stuk aangenamer maakte. Heel erg bedankt dat jullie 
mij op deze belangrijke dag willen bijstaan.
Dan zijn er nog vele vrienden, die al die jaren belangstellend de vorderingen van 
mijn promotieonderzoek hebben gevolgd. In het bijzonder wil ik Leontien bedan­
ken voor haar nimmer aflatende interesse gedurende dit lange traject.
Mijn huidige collega's van de Hans Berger Kliniek wil ik bedanken voorde aanmoedi­
ging en de gelegenheid die ik heb gekregen om mijn boekje af te ronden.
Mijn schoonouders, Diny en Fedde, wil ik bedanken voor het oppassen, zodat ik tijd 
had om aan mijn onderzoek te werken.
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Uiteindelijk was ik nooit zo ver gekomen zonder de onvoorwaardelijke steun en liefde 
van mijn ouders. Lieve mama, heel erg bedankt hiervoor. Wat is het jammer dat papa 
dit niet meer mee kan maken; hij zou ongetwijfeld vreselijk trots zijn geweest.
Tenslotte wil ik het thuisfront bedanken. Lieve Niels, heel erg bedankt voor je steun 
en "sponsoring" in de afgelopen jaren. Wat ben ik blij met jou en onze meisjes! Lieve 
Josefien en Feline, bedankt voor alle heerlijke momenten naast het werk, die het 
moeizame traject van een promotieonderzoek relativeren. Uiteindelijk is "mama" 
een nog mooiere titel dan doctor.
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